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Type-1 Diabetes (T1D) is an auto-immune disease in which the insulin-producing β-cells in the islets 
of Langerhans are destroyed, affecting over 20 million patients worldwide. Islet transplantation may 
offer a viable treatment strategy, but transplanted islet lifespan is limited by auto- and allo-immune 
responses and poor engraftment upon transplantation. Biofabrication of tissue engineered 
constructs encapsulating islets may offer a viable strategy, as this encapsulation may allow for 
immune-protection of the islets and circumvent issues associated with engraftment. Here, we 
describe for the first time a single-step fabrication procedure for tissue constructs incorporating 
isolated mouse islets with supporting endothelial progenitor cells. A platform for the fabrication of 
these constructs through co-axial micro-extrusion (Dual Ink Co-axial Bioprinter-1; DICAB-1) was 
first established, characterised and found to be biocompatible with MS1 and β-TC-6 cell lines 
(endothelial and beta-cells of murine origin, respectively). Bioprinted islets were found to survive 
fabrication procedures as well as secrete considerable amounts of insulin, albeit with substantial 
variability and with sub-optimal glucose responsivity. These results constitute a major step towards 
the development of a sophisticated platform in which constructs incorporating islets, supporting 
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of a one-year project undertaken at the Utrecht University and submitted as part of the 
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According to the Memorandum of Agreement between: Queensland University of Technology, University 
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Australian institution. The student initiates the Biofabrication Mobility Programme in a Master’s degree 
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in another Master’s degree at the overseas participating institution, hereinafter referred to host 
institution for a period of two semesters (60 EC in Europe) over one year.  
 
Students shall enrol in a Master’s degree at the home institution in accordance with the Biofabrication 
Mobility Programme specifications approved jointly by the institutions. Students will undertake a research 
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VI. Layman’s Summary 
 
Type-I diabetes (T1D) affects over 20 million people worldwide. In T1D, the body cannot produce 
enough insulin, which is important for regulating blood sugar. This is caused by the destruction of 
the β-cells that produce insulin by the patient’s own immune system in an auto-immune reaction. 
These β-cells are located in the islets of Langerhans. Therefore, one potential treatment is the 
transplantation of islets from donors to patients suffering from T1D. However, the wide-spread use 
of this treatment is hindered by a shortage in donor islets, and because the transplanted islets tend 
to die over time due to rejection or the auto-immune response. 
 A possible solution is therefore to encapsulate the islets in a material that protects them, but 
at the same time still allows for the release of insulin. To release insulin, it is important that the blood 
is still able to reach the islets which also supplies oxygen and nutrients to the islets. Therefore, a 
platform has been developed here for 3D-printing constructs with islets and blood vessel cells, which 
may meet these requirements. The constructs were printed with a new, custom-designed 3D-printer: 
the DICAB-1 (Dual Ink Co-Axial Bioprinter).  
DICAB-1 can print two materials (or cell types) at the same time into core and shell fibres. This 
was first confirmed with a simple gel and next with a cell-friendly bioink. It was then demonstrated 
that the platform could print core/shell-fibres with β-cells and blood vessel cells and that the cells 
survived the process. In a final set of experiments, it was investigated whether the DICAB-1 could 
print mouse islets and blood vessel progenitor cells. It was established that islets as well as these  
blood vessel progenitor cells also survived the printing and that the islets released insulin. However, 
it was also seen that the islets in these constructs did not match the natural insulin release response, 






Type-I diabetes (T1D) is an auto-immune disease that affects the pancreas and is characterised by 
the patient’s inability to produce (sufficient) insulin, which consequently affects blood glucose 
homeostasis. In 2014, it was estimated to affect over 20,000,000 patients worldwide.1 Long-standing 
T1D is associated with various major complications with considerable morbidity and mortality, 
including cardiovascular disease, stroke, blindness, kidney disease and ketoacidosis.2–5 In spite of 
significant effort and progress in treatment and management, still no effective cure or preventative 
measure exists for T1D.5 
 
In this respect, Tissue Engineering (TE) may offer a viable strategy. TE aims to fabricate tissue 
constructs in order to replace or repair diseased tissue and restore its function. TE has been applied 
with some clinical success for instance in the regeneration of skin6, urethra7 and cartilage8. TE has 
also shown potential for the treatment of T1D through the fabrication of endocrine pancreatic 
constructs.9,10 However, the field still faces several challenges in this area, some of which are 
associated specifically with T1D. A major hurdle that still needs to be overcome in TE for almost all 
applications is the development of proper vascularisation in tissue constructs. This is essential for 
the supply of nutrients and oxygen throughout the construct while simultaneously removing waste 
products.11,12 Specifically for T1D, another obstacle is associated with the mechanism of the disease. 
It is required that the tissue construct is in some way protected from the host immune system in 
order to prevent auto-immune destruction, in addition to immune rejection of implanted materials 
or tissues that may affect TE constructs in general. 
 Within TE, the recent science of Biofabrication is one of the most promising strategies for 
the fabrication of tissue constructs. It has been defined as “the automated generation of biologically 
functional products with structural organisation from living cells, bioactive molecules, biomaterials, 
cell aggregates such as micro-tissues, or hybrid cell-material constructs, through Bioprinting or 
Bioassembly and subsequent tissue maturation processes”.13 Informally, it is commonly used to refer 
to the application of Additive Manufacturing (AM; ‘3D-printing’) of cells and/or biomaterials to 
fabricate tissue constructs. 
 
This thesis is a report of a project dedicated towards the Biofabrication of endocrine pancreatic 
constructs. In the first following chapter, the focus will be on providing a framework of the 
mechanisms behind T1D, current treatments and background on TE and Biofabrication of endocrine 
pancreatic constructs. Then, the aims of the project and the developed platform will be outlined and 
the obtained results will be presented and discussed. Finally, a reflection on the project will be 






2.1 The pancreas and Type-I Diabetes 
The pancreas is a small organ situated behind the stomach in the abdominal cavity. It has major 
exocrine as well as endocrine functions. The exocrine functions of the pancreas mainly consist of the 
secretion of pancreatic juice into the duodenum, which contains both essential digestive enzymes as 
well as ions to neutralise the pH of the chime entering the intestine. The endocrine functions of the 
pancreas consist of the release of several hormones, which are required to maintain homeostasis. 
These include insulin, glucagon and somatostatin, all of which are released into the bloodstream. 
Insulin, the hormone that is most relevant here, is essential for the uptake and anabolism of glucose 
into for example glycogen in liver and muscles.5,14 
  In T1D, the synthesis and secretion of insulin is impeded. This is due to an auto-immune 
response towards the insulin-producing β-cells in the Islets of Langerhans. The immune response is 
mounted by a combination of autoreactive CD4+ and CD8+ T-lymphocytes, autoantibody producing 
B-lymphocytes as well as various activated parts of the innate immune system. The exact causes of 
the auto-immunity are not fully understood, but it is thought to be a combination of hereditary and 
environmental factors.5,15 In spite of the importance of the endocrine functions of the β-cells in the 
islets of Langerhans, they possess strongly limited regenerative potential which further declines with 
increasing age.16,17 As such, once β-cells are depleted, they are not naturally replenished and if left 
entirely untreated T1D is ultimately fatal due to the inability to maintain normoglycaemia (normal 
blood glucose levels). 
 
2.2 Current treatment and therapy 
Current treatment for T1D consists of the administration of exogenous recombinant insulin, which is 
required for patient survival. This can either occur via regular injection, or via an insulin pump.18 
Although this treatment offers some degree of control over of blood glucose levels, a long-term risk 
for severe complications is still present in patients undergoing treatment. These potential 
complications include cardiovascular disease, stroke, blindness, kidney disease and ketoacidosis.2–5 
Moreover, patients are prone to develop insensitivity to life threatening hypoglycaemia (low blood 
sugar).19–21 The necessity of regular injections or the insulin pump additionally constitute therapies 
that are considerably invasive and have a major impact on the daily life of the patients. As a final 
consideration, both therapies are also sub-optimal in that they fail to mimic the fine-tuned, glucose-
responsive natural secretion dynamics of the β-cells in the pancreas.22 
 A potential alternative treatment is whole organ pancreas transplantation which may 
restore long-term normoglycaemia. This is however an invasive procedure and exposes patients to 
considerable surgical risk. Patients furthermore require lifelong immune-suppressants. As a 
consequence, whole organ pancreas transplantation is commonly limited to patients who 
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additionally require kidney transplants which already necessitate the use of immune-suppressants 
and invasive surgery.23,24 In  patients with adequate kidney function, the potential benefits of whole 
organ transplantation may therefore not outweigh the risks.25 
As such, transplantation of pancreatic islets has been investigated and used as a potential 
alternative.26 In 2000, islet transplantation gained momentum with the establishment of the 
Edmonton protocol27, where considerable clinical success had been achieved with transplanted islets 
in combination with immune-suppression. Patients did not require exogenous insulin administration 
for an average of one year after transplantation. As a major advantage over whole organ 
transplantation, islet transplantation can be performed with minimally invasive surgery with 
minimal morbidity and risk of infection.28 However, there are some issues with the transplantation 
of islets. In addition to immunogenic rejection associated with transplantation (the allo-immune 
response), the auto-immune response poses an additional mechanism through which the immune 
system will reduce the effectivity of transplanted islets over time. As a consequence, in the original 
study of the Edmonton protocol all donor islet function was lost in all patients after 2 years post 
transplantation.27  
In order to improve the life span of these islets, extensive research has been conducted to 
establish various strategies to protect transplanted islets from auto-immune destruction and allo-
immune rejection.29,30 These will be reviewed at length further below. However, an additional factor 
is the general shortage in the availability of donor pancreata and islets, which further prevents wide-
scale application. Tissue Engineering (TE) may be a suitable strategy to combat both these challenges 
in two ways: by designing constructs in which β-cells are protected from immune responses and by 
designing solutions to circumvent the shortage in allogeneic islets.  
 
2.3 Tissue engineering for Type-I Diabetes 
There are three requirements that a successful tissue construct for T1D must meet (Fig. 1). First and 
foremost, there is the central clinical requirement: the cells or islets in the construct must establish 
reliable insulin secretion in response to high blood glucose levels (glucose stimulated insulin 
secretion; GSIS). For optimal GSIS, the primary concern is a reliable islet or β-cell source which 
possesses sufficient GSIS potential. The second requirement for a tissue construct is that it must 
protect the insulin-producing cells from the allo- and auto-immune reaction to prevent degradation. 
Third, it must allow for the diffusion of nutrients and oxygen into the construct to maintain cell 
viability and allow for the removal of waste products, potentially through the development of 
vascularisation. This will also be required for the detection of blood glucose levels for GSIS and the 





2.3.1 Cell sources and GSIS 
The first consideration in optimising GSIS is the cell source for the tissue construct. For TE in general, 
cells can be derived from cell lines, (induced) stem cells or primary cells.31 One limiting factor in the 
application of primary cells is that there is currently insufficient donor tissue available to act as a 
large-scale cell source. An additional limiting factor is that isolated islets and β-cells tend to lose 
function and de-differentiate in in vitro culture.32,33 
This de-differentiation in vitro has also long been an issue for establishing reliable β-cell 
lines. Recently, some strains have been developed that show more reliable GSIS34,35, but it will likely 
still be insufficient for applications past model systems. Although of value for fundamental research, 
cell lines are also unsuitable for clinical application due to their unlimited proliferation. Hence, 
research has focused on alternative cell sources that may be relevant for clinical application. Most 
notably, these include xenogeneic β-cells and islets36 or (induced) stem cells (re-) differentiated 
towards β-cell phenotype.37 
 
 
Primary β-cells or islets derived from porcine origin have been investigated most notably as a 
potential xenogeneic cell source, as porcine insulin and β-cells are highly similar to the human 
equivalents.37,38 For these cells, supply could be sufficient to meet clinical needs. There has been some 
clinical success using β-cells from porcine origin36,39, and some of the major issues in terms of 
xenogeneic acute rejection may be resolved through genetic engineering40. Some of the remaining 
drawbacks include potential zoonosis of diseases (such as porcine endogenous retroviral (PERV) 
sequences)41 and patients may oblige to xenotransplantation for ideological reasons. 
Alternatively, insulin-producing cells can be obtained from differentiation of stem cells 
Fig. 1: A schematic representation of the complex set of requirements for an optimal tissue engineered construct 
for T1D. If present, micro- or macro-encapsulation should allow for influx of oxygen and nutrients; most 
importantly glucose to allow for detection of blood glucose levels. Additionally, the construct should in some 
way protect the β-cells or islets from the host immune response. Finally, it should allow for the secretion of 
insulin. Therefore, it must support the development of vascularisation. Image partially adapted from Servier 
Smart Medical Art (ref. 121). 
13 
 
towards β-cell phenotype. Of particular interest are the recent developments in the formation of islet-
like cell clusters (or pseudo-islets). Embryonic stem cells (ESCs)42,43 or induced pluripotent stem cells 
(iPSCs)44,45 could both be suitable cell sources to this end. Major steps have been made in this field 
recently, and pseudo-islets that possess reliable GSIS have been generated from both ESCs and iPSCs. 
However, there are still several issues in terms of the full maturation of the stem cells. Not all 
mechanics and factors behind the maturation of these cells are understood yet, thus the generated 
cells still differ somewhat in insulin secretion dynamics from fully developed β-cells in vivo.46,47 
Although some of the ethical issues associated with the use of ESCs can be circumvented through the 
use of iPSCs, there are still major concerns around the possibility of teratoma formation.47 As a final 
(stem) cell source, mesenchymal stromal cells have also been investigated for differentiation towards 
insulin producing cells, but with limited success. They may, however, be useful as supporting 
cells.48,49  
   
It has been established that the environment of the β-cells has a major impact on their performance 
in GSIS. TE constructs employing biomaterials that closely resemble the natural extra-cellular matrix 
(ECM) may therefore enhance GSIS for any cell source. However, it has been shown furthermore that 
the surrounding cells in pancreatic islets, such as α-, δ- and endothelial cells, all play a role in 
regulating β-cell function.50 As such, whole islets still possess the most reliable GSIS, especially over 
individual β-cells.51–53 The main focus here will thus be on TE with whole pancreatic islets. It can be 
noted, however, that most strategies described here for islets could be applied for stem cell-derived 
pseudo-islets as well.  
 
2.3.2 Protection from the host immune system 
The second requirement for a successful TE pancreatic construct is the protection of the β-cells from 
the host immune response. Protection from the immune system will greatly increase the lifespan of 
a construct by avoiding allo- and auto-immune destruction. In addition, it may resolve some of the 
risks associated with the use of any allo-or xenogeneic cells. There are three distinct strategies to 
achieve such protection: shielding, immune-suppression and tolerogenesis. In the former, 
transplanted islets are attempted to be ‘hidden’ from the host immune system by a physical barrier, 
avoiding contact with the host immune system altogether. The second, immune-suppressive 
protection, is currently used most commonly and relies on the (systemic) suppression of immune 
responses through administration of immunosuppressive drugs. Finally, in tolerogenic approaches, 
it is attempted to sway the host immune system towards tolerance of the construct. 
 
Within immune-shielding, there are mainly two different strategies that are being employed to 
achieve protection from the host immune system: micro- and macro-encapsulation. The former 
refers to the encapsulation of individual or small amounts of islets; the latter refers to the 
encapsulation of a multitude of islets into one construct or in a more macroscopic, device-like set-up 
or bio-artificial pancreas.  
Both micro-encapsulation as well as macro-encapsulation have been employed with varying 
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degrees of success.30,54 Various materials have been used for the micro-encapsulation of islets, but 
alginate has by far been investigated most extensively.55 This strategy has led to several clinical trials. 
In the first clinical trial in 1994, insulin independence was achieved for 9 months56, albeit in 
combination with immune-suppressants for a previous kidney transplant. A primary goal of the 
encapsulation is, however, to avoid the use of immune-suppressants altogether. Conversely, most 
micro-encapsulated islets that do not require immune-suppressants have failed to achieve insulin 
independence in the clinic.55,57–59 
A major advantage of macro-encapsulation is that the device can be retrieved upon 
complications due to for example infection. Macro-encapsulation requires complex design, however, 
in order to allow for the passage of glucose and insulin while blocking cellular and humoral immune 
agents.60,61 To this extent, silicon semi-permeable membranes have been developed with pore sizes 
that fit this narrow window60,62 and recently this has been achieved with polycaprolactone (PCL)63. 
A larger construct as a result of macro-encapsulation may potentially exclude the use of minimally 
invasive surgery, however, and increase fibrotic overgrowth or foreign body responses61. 
 
Immune-suppressive therapy is the current gold standard protection from host immune-system. It 
increases the lifespan of non-encapsulated, transplanted islets27,64,65, but there are considerable 
drawbacks to their extensive use. They render patients more vulnerable to infection and many 
immune-suppressants are toxic to β-cells, affecting their function. In fact, they possess substantial 
toxicity in general and lead to major patient discomfort, with established side-effects including 
mouth and duodenal ulceration and bleeding, anaemia, leukopenia, nausea, vomiting and increased 
risk of certain cancers.55,66,67 There is a large array of different immune-suppressants with different 
working mechanisms, but a combination of various drugs is often required. Reviewing all here is 
beyond the scope of this thesis, but excellent recent reviews61,64 of their use in relation to islet 
transplantation are available. 
 
The final option for protection against host immune responses is the induction of (local) tolerance to 
the construct. Tolerogenesis may circumvent most of the drawbacks associated with immune-
suppressants, as it can be induced locally and specifically instead of systemically. It may be achieved 
through for example sustained release of anti-inflammatory cytokines or co-transplantation of (β-
cell specific) regulatory T-cells (T-regs). T-regs have previously been shown to be safe for human 
transplantation and are currently used in early phase clinical trials for T1D patients, further 
demonstrating the feasibility of this approach.68,69 
 
The various approaches for immune-protection are not necessarily mutually exclusive. On the 
contrary, macro- and micro-encapsulated islets are commonly still used in combination with 
immune-suppressive drugs. Alternatively, constructs that provide encapsulation could be 
additionally designed to accommodate tolerogenic agents. It is however unlikely that immune-
suppression and tolerogenesis are easily compatible. Several immune-suppressants aspecifically 
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downregulate T-lymphocytes and thereby T-regs or otherwise impede T-reg function.61 As such, this 
may interfere with the induction of tolerance and combinations of both (systemic) immune-
suppression and tolerogenesis may be difficult. Optimal tolerogenesis should nonetheless avoid the 
necessity of immune-suppressants, and considering the serious side-effects of immune-suppression, 
tolero-genesis may be a preferred strategy when feasible. 
 
2.3.3 Vascularisation and delivery of nutrients and oxygen 
A final requirement for the success of TE pancreatic constructs is the delivery of nutrients and oxygen 
throughout the constructs, while removing toxic waste.11,12 Mere diffusion is commonly insufficient: 
the maximum construct thickness for which diffusion would be sufficient is limited to 200 µm70; 
larger constructs are known to develop a necrotic core due to the lack of oxygen and nutrients.71 
Thus, TE constructs require some form of (pre-)vascularisation to reach more clinically relevant sizes 
without necrosis. Given the high metabolism of β-cells and necessity of secreting insulin into the 
bloodstream, vascularisation is of particular importance for TE with pancreatic islets. This is further 
signified by the fact that around 10% of islet volume consists of vasculature72, which is additionally 
over 10 times more fenestrated than in the exocrine pancreas.72,73 
 To achieve vascularisation, a multitude of strategies could be employed. This will only be 
briefly touched upon here, as these recently have been reviewed by the same author of this thesis.74 
One option is to integrate perfusable channels in the tissue construct, which could serve to supply 
nutrients throughout the construct during in vitro culture.75,76 At a later stage, these channels could 
be lined with endothelial (progenitor) cells in order to form blood vessel-like structures. Another 
option is patterned pre-vascularisation which may be obtained through co-culture of β-cells or islets 
with endothelial cells.77 Both options can be further stimulated through the administration of growth 
factors, such as vascular endothelial growth factor (VEGF).78 Following either option, the construct 
is likely to have an increased lifespan upon in vivo transplantation, when the vessel network 
anastomoses with the host circulation. 
 
2.4 Biofabrication and co-axial micro-extrusion 
It is evident that intelligent construct design is essential, considering the number and the complexity 
of the requirements for an optimal, tissue engineered endocrine pancreatic construct. In this respect, 
Biofabrication holds substantial promise as a method. The hallmark properties of Biofabrication 
include the ability to fabricate TE constructs of customised, complex architectures designed through 
Computer Aided Design (CAD). These can be fabricated with superior spatial control, which is 
inherently associated with AM. At the same time, Biofabrication can still offer the general benefits of 
TE and 3D-cell culture through the use of ECM-resembling biomaterials and growth factors, albeit 
that some cell viability may initially be lost in the printing process.13,79 Several different printing 
techniques are currently employed in Biofabrication, each associated with a set of (dis)advantages 
that renders different printing techniques suitable for different applications. Reviewing all of these 
techniques is beyond the scope of this thesis and several excellent reviews are available on this 
16 
 
topic.13,31,79,80 Rather, only the method employed in this project will be highlighted and attention will 
be paid to some interesting recent developments that are relevant to this project. 
 
One of the most commonly employed methods for 3D-Bioprinting is micro-extrusion (Fig. 2).31,81,82 
In micro-extrusion, the bioink (the biomaterials and/or cells that are being deposited) is 
continuously extruded through a nozzle. This leads to deposited fibres of bioink. The force required 
for the extrusion of this material can be supplied pneumatically (i.e. with air pressure) or 
mechanically (with a piston or screw). Although pneumatic extrusion can sometimes be inexpensive 
or easier to implement than mechanical alternatives, it is typically inferior in terms of control and 
resolution, as the applied force is less defined. The required build-up of air pressure which delays 
extrusion can furthermore lead to an “overshoot” of material upon initiation of printing. Mechanical 
set-ups in turn may have a lower maximum applied force, which may be limiting for the deposition 









Of interest here is the progress that has been made with the development of co-axial micro-extrusion. 
In these set-ups, at least two concentric nozzles are employed to simultaneously deposit a core 
material and shell material.83 This offers the possibility to deposit two different materials or cell types 
simultaneously in a spatially defined manner, or rapid crosslinking by supplying crosslinker-solution 
through either nozzle. By running crosslinker solution in the core, it has also been employed in the 
past to fabricate hollow structures for the fabrication of perfusable channels and/or blood 
vessels.84,85 
  
Figure 2: Three distinct, possible mechanisms 
for supplying the required pressure for micro-
extrusion. Micro-extrusion based on a piston 
and a screw can both be sub-categorised into 
“mechanical extrusion”.  
 
Edited from: Murphy et al. (ref. 31) 
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Biofabrication is not yet widely employed in the field of pancreatic tissue engineering.10,86–90 
Nonetheless, the limited previous instances of Biofabrication for endocrine pancreas tissue 
engineering will be discussed in the context of the present thesis in the discussion below. One 
potential additional use of a core/shell-deposition for pancreatic tissue engineering that has not 
previously been investigated may however be found in the fabrication of constructs with immune 
shielding. A core material containing the vulnerable β-cells may be printed simultaneously with a 
shell material that could offer shielding from the host immune system. In such an approach, the β-
cells will be protected from degradation while the core encapsulation material can be designed to 
meet the biological requirements of the cells. This could allow for encapsulation of the β-cells in a 
more cell-friendly material in the core as this material no longer needs to provide the protection from 





3. Project Aim and Platform 
3.1 Project aim 
In this project, it will be attempted to fabricate endocrine pancreatic tissue constructs encapsulating  
pancreatic islets through co-axial micro-extrusion. The project is part of an overarching ongoing 
research programme. The overarching aim of the research at large can be formulated as:  
 
“To establish a platform for the fabrication of endocrine pancreas-like tissue constructs in a co-axial 
printing set-up, incorporating endothelial cell network formation, which are protected from immune 
reactions and secrete insulin in response to glucose.”  
 
Within this broad framework, the focus of this thesis will be on the optimisation and characterisation 
of a new, customised printing set-up, establishing its biocompatibility and on the primary endocrine 
function of the pancreas: the secretion of insulin. The immune-protection and endothelial cell 
network formation are being investigated in other projects that are currently running in parallel. The 
platform that has been developed here will be outlined briefly below. Detailed methods and 
experimental set-up can be found in the Methods section. 
 
3.2 The Platform 
3.2.1 The Dual Ink Co-Axial Bioprinter (DICAB-1) 
For the fabrication of the tissue constructs, a custom 3D-printer with a co-axial extrusion set-up will 
be employed (Fig. 3). This newly developed printer will be referred to as the DICAB-1 (Dual Ink Co-
Axial Bioprinter 1), named for its ability to simultaneously, co-axially extrude a core and a shell fibre. 
The DICAB-1 features two independent extruders (Fig. 3B) which extrude through two concentric 
nozzles (Fig. 3CD) into core/shell-fibres. These extruders each consist of a stepper motor with an 
‘extruder rod’ (consisting of a threaded rod and nut assembly) applying mechanical force to a 
cartridge in the form of a 1 mL or 3 mL syringe. The syringes are placed in the DICAB-1 behind the 
‘doors’ which contain temperature regulation units. As such, the DICAB-1 could vary the temperature 
of the cartridge to suit the rheological requirements of various bioinks. The two extruders together 
with the co-axial nozzles and temperature control units make up the print head which can move 
independently along two axes: left/right along the x-axis and up/down along the z-axis. The three 
axes system is completed with movement of the build plate along the y-axis. 
In a way, the DICAB-1 can be seen as an automated version of the previously developed 
Biopen.91 As such, although the DICAB-1 is the first of its kind developed here, some of its hallmark 
components have been derived from the Biopen. The most important feature is the custom-
manufactured titanium nozzles (through selective laser melting), which are similar to the ones 
previously developed for the Biopen.91 However, where initially the Biopen relied on side-by-side 
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deposition of two materials through co-linear nozzles, the nozzles used here rely on a co-axial 
configuration which has been derived from later iterations of the Biopen resulting in core/shell 
deposition (Fig.3C and 3D).92,93 In the past, these nozzles have been employed in the co-axial melt 
extrusion of Alginate with PCL94 as well as fused deposition modelling (FDM) with poly-lactic acid 
(PLA)95 and most recently with the Biopen for in situ cartilage tissue engineering92,93. 
Notwithstanding the above, the co-linear nozzles mentioned previously would still be compatible 
with DICAB-1 for other applications beyond the scope of this thesis. 
 Two different sets of co-axial nozzles were employed for the experiments performed here. 
For most experiments, co-axial nozzles with a diameter of 449 ± 16 µm for the inner nozzle and a 
diameter of 1044 ± 24 µm for the outer nozzle were used. For the last set of experiments (see 
methods), a second set of nozzles was used with an inner and outer nozzle diameter of 502 ± 14 µm 
and 1241 ± 46 µm, respectively. 
 
Fig. 3: The DICAB-1 (A). 3D-models of the 
extruder heads (B) and the nozzle (C) have 
been included. The model of the nozzles in C 
displays the inner fluidics from the two-
cartridges into two co-axial nozzles. The 
printing end of the co-axial nozzles has been 
imaged with stereoscopic light microscopy 
(D), showing the co-axial structure. 3D-
renders in B and C have been made in-house 




Two biomaterials were used for the fabrication of fibres and constructs with DICAB-1. Initially, the 
cartridges were loaded with 20% Pluronic F-127 as an inexpensive material for performing 
preliminary calibration, optimisation and characterisation of the set-up. Pluronic F-127, or Lutrol, is 
a triblock co-polymer (poloxamer 407) consisting of two blocks of poly-ethylene glycol surrounding 
a block of polypropylene glycol. It gels at temperatures above 4°C when dissolved in water. Below 
4°C, it is an aqueous liquid.96 Because of its reversable gelation, it is commonly used as a sacrificial or 
fugitive ink to allow for fabrication of complex structures.97,98 Here, it is exclusively used as a material 
for preliminary experiments. Considering the cytotoxicity of Pluronic F-12796, different materials 
that are biologically and clinically more relevant have been used for encapsulating and printing cells. 
 
These experiments have been performed with a hybrid GelMA (gelatine methacryloyl)/alginate 
hydrogel. Both GelMA and alginate have been used extensively in tissue engineering and 
Biofabrication.79,99,100 Both are non-cytotoxic and biocompatible. When dissolved, they form a viscous 
liquid that can be crosslinked into a hydrogel. Alginate has been used extensively in the past in islet 
encapsulation strategies as described above, and it is a favourable material because of its 
straightforward crosslinking mechanism and favourable mechanical properties. Nonetheless, as it is 
a polysaccharide it does not offer cell attachment moieties and as thus it needs to be chemically 
modified in order to mimic the natural ECM.101,102 Contrarily, GelMA naturally offers abundant cell 
attachment moieties as it is derived from collagen, one of the major constituents of the ECM. GelMA 
is prepared through methacrylation of gelatine (a collagen derivative), which makes it photo-
crosslinkable in presence of a photo-initiator.103 By combining GelMA and alginate, a bioink can be 
designed that has favourable mechanical properties along with a cell-friendly ECM-like environment. 
 This hybrid hydrogel containing both GelMA and alginate had been previously defined, 
characterised and optimised for this project.104 The bioink consisted of 7.5% GelMA and 2% alginate. 
The rheology of the bioink had been studied and predicted to be most suitable for printing at a 
temperature of approximately 15°C. This is also the prime reason why the temperature regulation in 
the DICAB-1 is essential. A final benefit of the use of this hybrid bioink had also been hypothesised in 
these previous studies. It was expected that the positive charge of GelMA may interact with the 






Both endothelial cells and β-cells have been encapsulated in the bioink and incorporated in the 
constructs. Initially, fabricated constructs contained cells in single cell suspension derived from two 
cell lines: Mile Sven 1 (MS1) endothelial cells and β-TC-6 cells. Although cell lines are less suitable for 
translation to the clinic in the long-term, they posed a more cost-effective model system for some of 
the preliminary experiments compared to primary tissues or cells. The β-cell line, β-TC-6, has been 
used widely in the literature104–107 and is well understood. As their biological function in for example 
GSIS is not optimal, however, these cells have exclusively been used to validate cell survival during 
printing and culture. Additional experiments have been conducted to investigate clinical relevance 
and GSIS experiments were conducted with printed mouse islets (at the University of Adelaide), 
which are far superior to any cell line in terms of GSIS. These islets were supported by isolated 
endothelial progenitor cells (EPCs), which are also a more clinically relevant model than the MS1 
cells. 
 There are several reasons why both endothelial cells and islets have been incorporated into 
the constructs. One reason is that this allows for a proof-of-concept of co-delivery of two different 
cell types in co-axial fibres and demonstrates whether both endothelial as well as β-cells survive the 
printing and crosslinking process. More importantly, endothelial cells and in particular EPCs have 
previously been shown to have several beneficial effects on islet performance. The most obvious 
added value of EPCs is related to their potential for the development of vascularisation in the 
construct, which is primarily important for islet survival in the longer term through nutrient and 
oxygen delivery. Additionally, in future transplantation, this vascularisation will be essential to allow 
for the detection of host blood glucose levels and the transport of insulin. The presence of EPCs and 
their potential vascularisation have also been shown to improve engraftment upon 





3.2.4 Construct design 
Initially, core/shell-fibres were printed with Pluronic and GelMA/alginate bioink to optimise printer 
performance. However, the final design consisted of bioprinted tissue constructs. Co-axial fibres of 
the GelMA/Alginate bioink were in the x/y-plane and stacked in the z-direction (Fig. 4B). The bioink 
in the core contained the functional cells (β-TC-6 or pancreatic islets). The bioink in the shell  
incorporated supporting, endothelial cells, to demonstrate co-deposition of two different cell types 
(Fig. 4A). After printing, constructs were dual-crosslinked. First, the GelMA network was crosslinked 
with visible light. Second, the alginate network was ionically crosslinked in a CaCl2-bath. A more 
detailed description of the fabrication process is offered in the Methods section. Constructs 
incorporating primary mouse islets and EPCs consisted of a single-layer x/y-grid to limit size 




Fig. 4: The final construct design. The functional cells (islets or β-cells) are incorporated in the core-fibre, 
whereas the supporting endothelial cells are printed in the shell fibre, schematically represented in A. 





4.1 Preparation of materials 
4.1.1 Preparation of Pluronic ink 
Pluronic F-127 (Sigma-Aldrich) was suspended into deionised water (20% w/v) at 5°C. Full 
dissolution of Pluronic was allowed to occur overnight at 5°C. Before printing, Pluronic was dyed 
with common food colouring (red or blue) by mixing a small droplet of colouring into 50 mL stocks. 
Dyed Pluronic solutions were stored at 5°C until further use. 
  
4.1.2 Bioink material synthesis and labelling and bioink preparation 
Gelatine methacryloyl (GelMA) was prepared as described previously.103 Briefly, gelatine of medium 
molecular weight (porcine skin, Type A, 175 Bloom, Sigma-Aldrich; 10% w/v) was dissolved 
overnight in phosphate buffered saline (PBS) at 37°C. Next, GelMA was synthesised by direct reaction 
with methacrylic anhydride (Sigma-Aldrich) at 50°C for 4 hours. To end the reaction, the solution 
was diluted with PBS and neutralised to pH 7.4, after which the solution was dialysed for two weeks 
and consecutively freeze-dried. Freeze-dried GelMA was stored at -20°C until further use. For 
fluorescent bioink, GelMA was labelled with rhodamine-B iso-thiocyanate (Sigma-Aldrich): a red 
fluorescent label that covalently attaches to proteins. Labelling was performed by dissolving a small 
amount of dye (1% w/v) in DMSO. This solution was added to GelMA dissolved in PBS (5% w/v) and 
the reaction was allowed to proceed for 4 hours at room temperature (RT) shielded from light. 
Labelled GelMA was freeze-dried after two weeks of dialysis. All dialyses were performed in 
deionised water at RT which was refreshed twice per day. The above procedures were performed 
under sterile conditions. 
For the preparation of hybrid GelMA/alginate bioink, sodium alginate from brown algae 
(medium viscosity, Sigma-Aldrich; 2% w/v) was sterilised with UV-radiation for 20 minutes. Next, it 
was dissolved into sterile PBS at 37°C overnight with added 1% v/v streptomycin/penicillin 
(pen/strep; Life Technologies) and photo-initiator (LAP; lithium phenyl-2,4,6-trimethyl-benzoyl-
phosphinate; 0.06%; Sigma-Aldrich (Wollongong) / TCI (Adelaide)). Sodium alginate solution was 
stored at 4°C until further use. Upon requirement of bioink, alginate solution was heated to 37°C and 
GelMA was stepwise added in small amounts to finally add up to a total concentration of 7.5% and 
dissolved by vigorous vortexing. The bioink was stored overnight at 37°C before use on the next day, 
to ensure complete dissolution of GelMA and mixing of the alginate and GelMA polymer networks. 
For cell or islet encapsulation and printing experiments, initial bioink concentrations were 
adjusted to allow re-suspension of cells in medium into the bioink. 1.25× Concentrated bioink was 
similarly prepared as described above. Adjusted bioink concentrations were chosen (2.5% Alginate; 
9.375% GelMA) to allow for suspension of concentrated cells or islets with medium in a 1:4 (medium 




4.2 2D-Cell culture 
MS1 cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM; Life Technologies) further 
supplemented with 5% v/v foetal bovine serum (FBS), 1% v/v pen/strep (Life Technologies) and 1% 
v/v Glutamax (Life Technologies) under standard cell culture conditions (37°C, 5% CO2). Cells were 
passaged at 90% confluency and entered the experiment at passage 10. Beta-TC-6 (β-TC-6) cells were 
similarly cultured in DMEM supplemented with 15% v/v FBS and 1% v/v pen/strep. MS1 cells were 
passaged 1:20, whereas β-TC-6 cells were passaged 1:3. β-TC-6 cells entered the experiment at 
passage 40 or 41 (from a previously established stock at passage 38).  
 
4.3 Life/dead staining 
For all non-primary cell printing and encapsulation, calcein AM/PI staining (calcein acetoxymethyl 
ester/propidium iodide; Sigma-Aldrich) was used. Constructs were taken from culture and washed 
with PBS. Next, constructs were incubated in 500 µL calcein AM (5 µM in PBS) for 15 minutes at 37°C, 
5% CO2. A small amount of PI (final concentration 1 µg/mL) was added to the solution and culture 
was continued for 5 more minutes in the same conditions. Staining solution was replaced with PBS 
and constructs were imaged with fluorescence microscopy (Zeiss Axiovert CF40). For islet printing 
experiments, FDA/PI (fluorescein diacetate/propidium iodide; Sigma-Aldrich) staining was 
performed instead. Constructs or free islets were washed with PBS and consecutively placed in 1 mM 
FDA and 5 µg/mL PI dissolved in PBS. Samples were incubated for 10 minutes and washed again with 
PBS. Images were recorded through confocal (Olympus FV3000) or fluorescence microscopy 
(Olympus CKX41) within an hour. 
 
4.4 Cell proliferation/metabolism 
To keep track of total cell metabolism as a measure of both proliferation and cell function, PrestoBlue 
assays were performed. Briefly, constructs were washed in PBS and placed into wells containing 1 
mL standard culture medium supplemented with 1% PrestoBlue (ThermoFisher Scientific) and 
incubated for 4 hours (37°C, 5% CO2). Supernatants were collected and fluorescence of supernatants 
was recorded at 544/590 nm in duplicates (BMG Labtech FLUOstar Omega). Constructs were washed 
in PBS twice before return to culture at intermediate time points. 
 
4.5 MS1 cell encapsulation 
MS1 cells were trypsinised from 2D-culture and suspended in medium containing 0.06% LAP and 10 
ng/mL recombinant mouse VEGF. Cell suspensions were re-suspended into bioink containing 0.06% 
w/v LAP and 1% v/v pen/strep at approximately 2 million cells mL-1. Cells suspended in bioink were 
cast into cylindrical custom moulds (5 mm diameter, 2 mm height). Consecutively, constructs were 
crosslinked first in visible light at 405 nm wavelength (Omnicure, BVL-4.LC, output 15%) for 60 
seconds. Second, ionic crosslinking of the alginate network occurred in CaCl2-baths (2% w/v; CaCl2-
dihydrate extra pure, Scharlau) for 10 minutes. Constructs were then cultured for three weeks in MS1 
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culture medium further supplemented with VEGF (10 ng/mL; Gibco). Cell viability (live/dead) and 
metabolism (PrestoBlue) was investigated at t = 0, t = 7, t = 14 and t = 21 days.  
 
4.6 Printing of co-axial fibres with Pluronic and (labelled) bioink  
4.6.1 Printer optimisation with Pluronic 
All prints were performed onto standard microscope slides. Initially, the build plate distance was 
optimised by performing sweeps of different distances ranging from 0.7 to 1.3 mm at a feed rate of 
400 mm/min and extrusion rate of 0.1 (-) with a core/shell-ratio of 1:1. Extrusion rate was defined  
as the distance (in mm) the extruding piston moved down per distance moved by the printhead (in 
mm). Build plate distance was optimised for fibre continuity, minimal variability in diameter and 
subjective print quality (i.e. to which degree the print matches the path of the G-code) to 0.9 mm, 
calibrated by lowering the nozzle to contact with the build plate before each print. Extrusion rates 
were consecutively optimised to 0.06 (-) for minimal variability in diameter by performing a sweep 
of extrusion rates (Fig. S1). Extrusion rates below 0.06 (-) led to recurring intermittent fibre printing 
due insufficient material deposition. The following, optimised parameters were used in all 
consecutive prints: 400 mm/min feed rate, 0.9 mm build plate distance and 0.06 (-) extrusion rate. 
All prints with Pluronic were performed with temperature system set to 12°C to decrease viscosity 
during printing, although actual cartridge temperature could not be measured and is expected to be 
higher due to single-sided contact with temperature regulation units. 
 
4.6.2 Fabrication of co-axial fibres with Pluronic 
Print G-codes were manually coded without additional CAD or slicing software. Codes have been 
provided in the appendix (Appendix B). Prints were performed at core : shell extrusion ratios of 4 : 
96 and 16 : 84. Pluronic labelled with blue and red food dye was extruded through core and shell, 
respectively. Pictures were recorded with stereoscopic microscopy (Leica M205A) and core and shell 
fibre diameters were measured in ImageJ software from two independent prints performed on 
different days in triplicate.  
  
4.6.3 Fabrication of GelMA/alginate co-axial fibres 
For printing GelMA/alginate bioink, different parameters needed to be established for reliable 
extrusion. Parameters for printing core/shell-fibres with a diameter ratio of approximately 1:1 were 
optimised through trial and error to an extrusion rate of 0.010 (-) at a feed rate of 400 mm/min with 
system temperatures set to 15°C onto glass slides pre-cooled to 5°C at a distance of 0.7 mm.  Due to 
time constraints, material cost and labour intensity of material synthesis, no complete parameter 
optimisation sweeps were performed with bioink. Fluorescently labelled bioink (5% labelled GelMA 
of total GelMA content) in the core was co-printed with unlabelled bioink in the shell and 
consecutively photo- and ionically crosslinked as described above. Images were recorded directly 






4.7 2D MS1 and β-TC-6 metabolism and proliferation assays 
MS1 and β-TC-6 cells were cultured in β-TC-6 culture medium in T75 flasks in triplicates. At t = 0, 1.6 
million cells were seeded. Cell counts were performed at t = 0, t = 1 and t =3 days because of the high 
proliferative rate of MS1 cells (Invitrogen Countess 1754B). At the same time points, total metabolic 
rates were established with PrestoBlue assays as described above prior to cell counts. 
 
4.8 Bioprinting MS1 and β-TC-6 cells 
β-TC-6 and MS1 cells were expanded to sufficient cell numbers in 2D-cell culture flasks and 
encapsulated in bioink as described above. β-TC-6 cells were encapsulated at approximately 6 million 
cells mL-1, whereas MS1 cells were encapsulated at approximately 1 million cells mL-1. Co-axial fibres 
were printed at an extrusion rate of 0.010 (-) with a feed rate of 400 mm/min with system 
temperature settings at 15°C onto pre-cooled glass slides (5°C). Cell viability was established at t = 1 
and t =7 days post printing as described above. 
 For attempted CD31 labelling, small parts of fibres were excised from prints and fixed with 
3.7% PFA (paraformaldehyde) for 20 minutes at RT. Samples were washed with PBS and incubated 
for 1 hr at RT in 1% BSA (bovine serum albumin) in PBS. Fibres incubated with directly conjugated 
anti-mouse CD31/FITC monoclonal antibody (ThermoFisher, 11-0311-82) for 1 hr or 24 hrs in 1:20 
and 1:50 dilutions (in different attempts). Samples were washed again and stained with DAPI for 5 
minutes prior to imaging with fluorescence microscopy.  
 
4.9 Fabrication of 3D-constructs with bioink 
6-layered constructs of approximately 1.5 × 1.5 × 0.5 cm were fabricated at previously mentioned 
parameters for GelMA/alginate bioink. Trace fluorescently labelled GelMA (5% of total GelMA 
content) was incorporated in the core, whereas shell fibres were unlabelled. During deposition of 
each layer, bioink was crosslinked for 40 seconds with visible light (Omnicure, BVL-4.LC, output 
15%). After deposition of the first two layers, partial ionic crosslinking was achieved by dropping 
small volumes (40 μL total) of CaCl2-solution (2% w/v) evenly onto the printed bioink. Ionic 
crosslinking was completed after all layers were deposited by submerging constructs in 2% CaCl2-
baths for 10 minutes. Images were recorded through stereoscopic microscopy (Leica M205A). 
 
4.10 Murine EPC and islet isolation and culture* 
4.10.1 Isolation and culture of murine islets 
Mice (C57BL/6) were euthanised according to all ethical standards and guidelines. Pancreata were 
isolated and perfused with 3 mL cold collagenase solution. Samples were allowed to reach 37°C and 
 
* Murine EPC and islet isolation was performed by Daniella Penko at the University of Adelaide 
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30 mL of islet wash medium (M199; Gibco) was added. Samples were shaken hard and vortexed, 
before being spun down at 300G for 3 minutes. Supernatants were decanted; this wash procedure 
was repeated. Degraded pancreata were then sieved twice. Islets were then separated using 
Lymphoprep (Stemcell Technologies) and finally washed several times using islet wash medium. 
Islets were cultured for one day in complete islet medium (RPMI 1640; Gibco; supplemented with 
10% FBS and 1% pen/strep (v/v)) and counted under light microscopy (Olympus CKX41) before 
printing. 
 
4.10.2 Isolation and culture of murine EPCs 
Mice (C57BL/6) were euthanised according to all ethical standards and guidelines. Femurs and tibia 
were isolated and separated from muscle and tendons. Ends of tibia and femurs were cut off and bone 
marrow was flushed out with 37°C EPC wash medium (HUVE supplemented with 20% FBS; Gibco) 
applied through a 23G needle. Bone marrow was broken down and blended into single cell 
suspension through pipetting up and down through EPC wash medium. T25 cell culture flasks were 
coated with fibronectin (500 μL per flask at 50 μg/mL; Roche).  Cells were counted and transferred 
to fibronectin-coated T25 flasks. Cells were allowed to adhere for 1 day in EPC culture medium 
(HUVE with 20% FBS, further supplemented with heparin (0.045 μg/mL; BD Bioscience) and 
endothelial growth factor (0.045 μg/mL; BD Bioscience); 37°C, 5% CO2). Non-adherent cells were 
removed and EPCs were cultured in EPC-medium for 6 days before printing. 
 
4.11 Islet/EPC-construct fabrication and culture 
DICAB-1 was sterilised with 70% ethanol and moved into a PC2 Biosafety Cabinet. Nozzles, 
cartridges, petri-dishes, tweezers and needle tips were sterilised with 70% ethanol which was 
allowed to evaporate for 30 minutes. Islets or EPCs were collected and counted as described above 
and re-suspended in LAP-supplemented (0.06% v/v) islet medium at 2500 islets mL-1 or 12.5 million 
cells mL-1. Next, resuspended islets or EPCs were encapsulated into 1.25× concentrated bioink (pre-
warmed to 37°C), resulting in a final 1× concentration of bioink (7.5% GelMA / 2.0% alginate) with 
500 islets mL-1 or 2.5 million EPCs mL-1. Bioink with suspended islets or EPCs was loaded into core 
or shell cartridges, respectively, and consecutively pre-cooled on ice for 5 minutes to ensure 
increased viscosity and printability. Constructs consisted of single-layer x/y-grids of 2 cm by 2 cm 
with 0.5 cm fibre spacing. Constructs were photo-crosslinked during printing for 40 seconds at 10% 
intensity (OmniCure LX505) at an approximate distance of 1.0 cm, followed by 40 seconds photo-
crosslinking post-printing. Constructs were consecutively ionically crosslinked in 2% CaCl2-baths 
(BDH AlanaR) for 10 minutes, before transfer to non-adherent 6-well plates for culture in 2 mL 
complete islet medium. Constructs and free-floating islets were investigated at t = 1 and t = 3 days 
post-printing. 
 
4.12 Glucose Stimulated Insulin Secretion 
Constructs containing islets (core) and EPCs (shell), constructs containing islets only, negative 
28 
 
controls (constructs without islets or EPCs) and free-floating islets were carefully collected from 
culture and placed in Eppendorf cups. Constructs were washed with Krebs buffer supplemented with 
2 mM glucose and consecutively allowed to recover with the same buffer for 30 minutes. Next, 
constructs or free islets were incubated for one hour with open lids (37°C; 5% CO2) in Krebs buffer 
containing 2 mM and consecutively 20 mM glucose. After both incubations, supernatants were 
collected for further investigation. 
 Supernatants were then used in an insulin-detecting ELISA (Mercodia), following the 
manufacturer’s instructions. Briefly, small volumes of supernatants were pipetted into 96-well plates 
coated with monoclonal anti-insulin (murine) in duplicates. Peroxidase-conjugated monoclonal anti-
insulin was added and samples were incubated for 2 hours at RT. Wells were washed several times 
and substrate (3,3’,5,5’-tetramethylbenzidine) was added to each well; reactions were allowed to 
proceed at RT for 15 minutes before being halted with 0.5M H2SO4. Optical density of the wells was 
then read within 30 minutes at 450 nm (Bio-Rad Model 680). Negative controls were subtracted as 
blanks for constructs, whereas regular blanks were subtracted from free-floating islets. Standard 
curves based on manufacturer’s calibrator samples were used to calculate results (see statistical 
analyses below); a 1:10 dilution was included for the 20 mM glucose samples in order to ensure 
results were within reliable detection range.  
 
4.13 Hypoxia in scaffolds 
Single-layer scaffolds of 2.0 by 2.0 cm (i.e. the same scaffold design used for printing islets and EPCs) 
were fabricated as described previously. For these experiments, EPCs were incorporated into both 
shell and core fibres of the scaffold. At one day post-printing, scaffolds were cultured at normoxic 
conditions for 4 hours at 37°C (5% CO2) in islet culture medium supplemented with a hypoxia reagent 
(Invitrogen Image-iT green hypoxia reagent) at 1 μL/mL. Scaffolds were then cut into smaller 
samples (0.5 by 0.5 cm) to allow for imaging with confocal microscopy (Olympus FV3000). Hypoxic 
and normoxic controls were established by plating EPCs in 6-well plates in the same medium for 4 
hours in 1% O2 or normal oxygen concentrations, respectively. Cells were then trypsinised and 
similarly imaged through confocal microscopy.  
 For quantifiable data, flow cytometry (BD FACSCanto II) was used. Scaffolds and controls 
were cultured for 4 hours in conditions described above, in medium supplemented with 0.2 μL/mL 
hypoxia reagent. Scaffolds were then digested using a mixture of enzymes (Gibco TrypLE Express) 
with intermittent vortexing and pipetting up and down until full degradation. Hypoxic and normoxic 
controls were trypsinised and data were obtained through flow cytometry in triplicates and analysed 
with FCS Express 6 Flow Cytometry Software. 
 
4.14 Statistical analyses 
All statistical analyses have been performed in standard IBM SPSS software. Where relevant, data are 
shown with the 95% CI (confidence interval) or the standard deviation. Unless otherwise stated, tests 
for significantly different means were performed with one-way ANOVAs with Bonferroni post-hoc 
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tests. In a few cases (explicitly stated in figure legends), the ANOVA assumption of homogeneity of 
variance was not met (established through Levene’s test for homogeneity of variances) and Welch’s 
test was used instead.  
 For the analysis of the GSIS, a standard curve was plotted based on reagents from the 
manufacturer. A cubic spline regression was employed to plot the curve, from which the unknown 
concentrations were interpolated in duplicates. Two independent experiments were performed with 
a sample size of three, leading to a total N = 6. Duplicates were averaged and data are represented 







5.1 Proof-of-concept printing of co-axial fibres 
First, the properties of the printer were evaluated and it was investigated whether and how co-axial 
fibres could be fabricated reliably. Initially, 20% Pluronic F-127 (Lutrol) was used, before moving to 
the less readily available, more labour-intensive and costlier bioink. 
 
5.1.1 Pluronic F-127 
As an initial test, Pluronic was printed through both core and shell nozzles. In order to visualise the 
core/shell-structure in the co-axial fibres, the Pluronic in the core and shell cartridge were coloured 
with blue and red food dye, respectively. Two examples of the resulting core/shell-fibres with 

























Using an extrusion ratio of 4 : 96 (core : shell), it was established that it was possible to fabricate 
fibres of a total diameter of 1.45 ± 0.044 mm and a core diameter of  0.46 ± 0.091 mm, represented 
in Fig. 5A.  Varrying this extrusion ratio, but not the total extrusion rate, was found to affect the 
core/shell-diameter ratio, but also to a smaller degree the total (outer) diameter. Extruding at a ratio 
of 16 : 84 (core : shell) was found to result in fibres with a total diameter of 1.27 ± 0.092 mm and a 
core diamter of 0.67 ± 0.087 mm (Fig. 5B). As such, it had been confirmed that the platform is capable 
of producing core/shell-fibres with reasonable control over fibre diameters and core/shell-ratios. 
Next, the parameters were further optimised to constrain total fibre diameter to within 1 mm (Fig. 
S1). Given the limited clinical relevance of Pluronic due to its cytotoxicity96, however, no further 
Fig. 5: Co-axial fibres printed with the DICAB-1 with two different core and fibre diameters. Pluronic F-
127 was extruded through both core and shell nozzles at two different ratios (4:96 in A and 16:84 in B) to 
achieve different core diameters. Pluronic F-127 was dyed with a blue food colouring dye or a red food 
colouring dye to visualise core and shell fibres, respectively.  
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experiments were conducted relying on this material and it was next evaluated whether fabrication 
of co-axial fibres was feasible with the GelMA/Alginate-bioink. 
 
5.1.2 Fabricating co-axial fibres with GelMA/alginate Bioink 
Thus, as a next step, the GelMA/alginate bioink was used to fabricate co-axial fibres. This was first 
demonstrated in a cell-free proof of concept. To still visualise a core/shell-structure in the fibres, a 
fluorescently labelled GelMA was synthesised. Before bioink preparation, GelMA was covalently 
labelled with rhodamine-B-isothiocyanate. A small portion of this labelled GelMA (5% of total GelMA 
content) was blended into the bioink. The resulting labelled bioink was loaded into the cartridge  for 
the extrusion of the core fibres. The concentration of unlabelled GelMA in the core was slightly 
adjusted to make sure the total GelMA concentration remained consistent at 7.5% between core and 
shell fibres. The shell cartridge for these prints was loaded with unaltered 7.5%/2% GelMA/alginate 
bioink.  
 Fibres were printed and consecutively photo-crosslinked with visible light and ionically 
crosslinked in 2% CaCl2 baths. Immediately after printing, fibres were analysed with fluorescence 
microscopy (Fig. 6B). The fluorescent channel was superimposed (Fig. 6C) with a brightfield image 
(Fig. 6A) in order to clearly visualise the whole fibre. In these images, only the centre of the fibres 
shows fluorescence. The fluorescently labelled GelMA is therefore contained within the core of the 
fibres, indicating successful fabrication of co-axial fibres. Some red can be observed outside the 
border of the printed co-axial fibres, but this is attributed to reflection of fluorescence on the glass 
microscope plate surface. 
 Two additional observations can be made from the imaged fibres. First, even in the 
brightfield image (Fig. 6A), a core/shell-structure seems observable that matches the structure 
observable in the fluorescent channel. This is somewhat unexpected, since apart from a trace amount 
of labelled bioink, the material of core and shell are identical. A more continuous and monolithic 
appearance of the fibre in the brightfield channel was therefore expected. It is unsure whether these 
borders are an effect of the extrusion through a co-axial nozzle or a small difference in material 
properties due to the presence of labelled GelMA. The direct area surrounding the core fibres also 
shows some mild fluorescence that decreases with distance. This may indicate some limited diffusion 
of labelled GelMA into part of the shell fibres prior to fibre crosslinking. Nonetheless, a clear shell 








   
Fig. 6: Co-axial fibres of GelMA/alginate bioink printed with DICAB-1. Images of  brightfield (A), fluorescent 
channel (B) and a superposition of both channels (C) have been displayed of an extruded fibre with 
GelMA/alginate bioink with trace (5% of total GelMA content) fluorescently labelled GelMA in the core.  
32 
 
5.1.3 Fabrication of 3D-constructs with GelMA/alginate bioink 
Since of printing core/shell-fibres with the platform had been confirmed, it was next investigated 
whether it was feasible to fabricate 3-dimensional constructs with stacked fibres in the z-direction. 
To this end, labelled (core) and unlabelled bioink (shell) was printed into co-axial fibres which were 
deposited in an x/y-grid in layers. During printing of each layer, bioink was crosslinked with visible 
light. Six layers were printed resulting in constructs with a height of approximately 0.5 cm.  
 In initial prints, it was found that in spite of the current temperature control set-up, cooling 
was not effective enough to increase viscosity for reliable fibre stacking. It was decided to pre-cool 
the glass collection slides to 5°C to maintain lower temperatures after deposition and during 
crosslinking. Additionally, partial ionic crosslinking was allowed to occur by dropping small volumes 
of CaCl2-solution onto the first two layers after printing of each layer. This also led to partial 
crosslinking of the additional layers upon deposition, increasing shape fidelity despite lower 
viscosities. 
 With these additional measures, 6-layered constructs could be printed with reasonable 
control (Fig. 7). Although most porosity could be maintained, pore size was not consistent within the 
constructs, with decreased pore size around the borders. Occasionally, pores were still completely 
blocked in corners as exemplified in Fig. 7. These limits in print quality were attributed to sub-
optimal cooling as fibres were still somewhat liquid upon deposition, leading to ‘leaking’ into pores 
upon stacking of additional layers. This sub-optimal cooling was confirmed as temperature 
regulation units were unable to reach target temperatures at the interface with the cartridge, which 
suggests bioink temperatures were higher still within the cartridges. In future improved iterations  
  
Fig. 7: Top-view of a 6-layered construct with labelled bioink (pink, core) and unlabelled bioink (colourless). Print 
quality was significantly inferior compared to single fibres, in spite of additional measures to improve print quality. 
Porosity can be observed to be maintained but inconsistent and core/shell-structure was less apparent. Image 
recorded through stereoscopic microscopy. 
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of DICAB-1, temperature control will be enhanced and it is expected that improved print quality with 
fibre stacking should be feasible at that stage.  
Most labelled bioink filaments, which appear pink in light microscopy, were localised 
towards the core of the fibres. However, in line with insufficient viscosity for layer stacking, the 
prolonged printing time before crosslinking led to increased blending between core and shell fibres, 
with core/shell-structure less apparent than in single fibres (Fig. 5 and Fig. 6). Additionally, minor 
shifts in position between stacked fibres may lead to less apparent localisation of labelled bioink in 
core fibres in a top-view. 
 
Based on these observations, it was established that the current generation of DICAB-1 only 
possessed limited capability for the reliable fabrication of multi-layered constructs despite additional 
measures for shape fidelity such as pre-cooled collection slides and moderate ionic and photo-
crosslinking during printing. Before larger multi-layered constructs can be fabricated with consistent 
porosity and more reliable core/shell-structure, improved cooling will be a primary necessity. 
 
5.2 Encapsulation of MS1 cells 
It was investigated whether the encapsulation and crosslinking processes by themselves, 
irrespective of printing, were cell-friendly and whether the 7.5%/2% GelMA/alginate-bioink could 
sustain a long-term 3D-cell culture. To this end, a mouse endothelial cell line (Mile Sven-1; MS1) was 
first grown to sufficient cell numbers in traditional 2D-cell culture flasks and consecutively 
encapsulated in bioink. Cells encapsulated in bioink were then mould-casted into custom cylinders 
(5 mm diameter, 1 mm height). The bioink was then photo-crosslinked and ionically crosslinked as 
described previously. The resulting constructs were cultured for three weeks in presence of 10 ng/ml 
recombinant mouse VEGF (vascular endothelial growth factor) supplemented in the culture medium.  
VEGF is a growth factor which enhances the development of vascularisation through 
angiogenesis. It was chosen as a suitable supplement as it has been used in the past to stimulate 
vascularisation in the context of encapsulated islets112 and it furthermore plays a major role in the 
vascularisation of islets in vivo, where it is secreted by pancreatic endocrine cells78.  
 
In order to evaluate cell viability after encapsulation and crosslinking, live-dead staining was 
performed at 1 day after encapsulation (Fig. 8A). Additionally, viability was evaluated after 21 days 
to investigate whether the GelMA/alginate hydrogel could sustain long-term culture (Fig. 8B). At day 
1, it can be seen that cells are predominantly present in single-cell suspension, which can be expected 
at such short time after trypsinisation from 2D-cell culture. Most cells stain green indicating good 
viability, although there are a few cell agglomerations that seem to have died. These may be a result 
of incomplete trypsinisation prior to encapsulation, and due to their increased size they may have 
been subjected to increased shear stress during mould casting. At 21 days, over-all cell viability is 
maintained and cells have proliferated substantially over time. In addition, cell spreading and some 
alignment can be observed as a sign of biological activity. 
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In order to further evaluate the cell-spreading and morphology over time, higher magnification 
images were also obtained at intermittent 7-day intervals. These have been depicted in Fig. 9. In 
particular, it was investigated whether, as a result of supplemented VEGF in the medium, MS1 cells 
formed an endothelial cell network. At t = 7 and t = 14 days, only limited local cell spreading was 
observed at higher magnifications (Fig. 9A and 9B), which was slightly more substantial at 14 days 
as can be expected. At t = 21 days, cell spreading was more obvious and continuous throughout the 
construct (Fig. 9C, 9D and 9E), which indicates biological activity is maintained during culture. The 
increasing cell density over time which was also observed in Fig. 8A and Fig. 8B was also mirrored 
at these higher magnifications. In general, observed cell alignment and proliferation suggests 
sustained biological activity of MS1 cells over-time.  
Although cell alignment was observed, no vascular structures or continuous endothelial cell 
network formation were observed. In the future, these experiments may be repeated to further 
investigate the development of vascularisation. Perhaps concentrations of added VEGF may still be 
optimised. Most importantly, the visualisation may be improved through the use of confocal 
microscopy in order to also investigate lumen formation of potential endothelial cell networks, which 
is an essential part of the development of functional vasculature. 
 
As an additional measure of biological activity of the encapsulated MS1 cells, and to confirm 
proliferation, total cell metabolism was tracked over time at seven-day intervals (Fig. 10). In line 
with the observed proliferation in images displayed in Fig. 8 and Fig. 9, the total metabolic rate of 
the encapsulated MS1 cells increased over time. During the first two weeks, proliferation resembles 
an exponential growth, which somewhat slows down or staves off after the second week. The 
decreased growth during the third week may be due to the hydrogel achieving a saturated population 




Fig. 8: Live/dead staining (calcein AM/PI) of encapsulated MS1 endothelial cells in GelMA/alginate bioink. Cells were 
encapsulated at 5 million mL-1 and consecutively cultured over the course of three weeks in MS1 medium in the presence 














Fig. 9: Several higher magnification images of 
encapsulated MS1 cells in bioink at the 7 day 
intervals, again visualized through live/dead staining 
(calcein AM/PI). Limited, individual cell spreading 
was observed at t = 7 days (A). By 14 days (B), 
moderate alignment was observed with small 
amounts of cells and cell spreading was still 
observed. At t = 21 days, substantial cell alignment 
and spreading was observed throughout the 
construct as exemplified by C, D and E. In all images, 





The combined results of the MS1 encapsulation in Fig. 8, Fig. 9 and Fig. 10 show that cells are viable 
both shortly after encapsulation and crosslinking, as well as after long term culture and remain 
metabolically and biologically active. These data suggest the crosslinking process is sufficiently cell-
friendly and the platform can support cell culture over at least three weeks. 
 
 
5.3 Establishing co-culture of MS1 and β-TC-6 cells 
Since the printability of the GelMA/alginate bioink was shown and basic cell compatibility had been 
confirmed in encapsulation experiments, it was next established whether the present printing 
platform was cell-compatible. To this extent, two different cell lines were co-printed in core and shell 
fibres. Before these experiments could be conducted, however, it is necessary to design a feasible co-
culture platform for the two cell-types. 
 There are some considerations to take into account before a co-culture can viably be 
established of two different cell types.77 Firstly, a cell culture medium needs to be established that 
can support both cell types. As different cell types commonly have different standard culture media, 
this often results in a mismatch in optimal conditions for both cell types. In this platform, a β-cell line 
and an endothelial cell line were going to be co-cultured: β-TC-6 and MS1 cells, respectively. 
Considering that the biological function of the β-cells was clinically most relevant and important, it 
was first attempted to establish a co-culture relying on the optimised β-TC-6 culture medium. Thus, 
it was first investigated if β-TC-6 medium was able to support MS1 cell culture in traditional 2D-cell 
culture flasks. This was confirmed and there was no noticeable difference in MS1 morphology or 
behaviour across the different culture media in standard 2D-culture (data not shown). 
Fig. 10: Total metabolic rate of encapsulated MS1 cells in GelMA/alginate bioink. Cells were encapsulated at 5 million mL-1 
and consecutively cultured over the course of three weeks in MS1 medium in the presence of VEGF. Total Metabolic Rate 
has been represented as relative to the mean rate at t = 0 days (100%).  N = 3, error bars denote the 95% CI. 
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A second consideration for the co-culture of two different cell types is their relative proliferative and 
metabolic rates. A considerable difference between cell types in either of these can result in 
overgrowth of one cell type or starvation due to outcompeting for nutrients, respectively. This would 
result in an unstable co-culture where only one cell type remains after some time in culture. 
 In order to obtain a quantified indication of the relative proliferative and metabolic rates of 
the two cell lines, a simple 2D-culture system was employed. Cells were cultured for 3 days and 
counted at day 1 and 3. In addition, their total metabolic rate was measured at the same time points 
(prior to counting). 
 The results have been depicted below in Fig. 11. Based on these data, it is apparent that MS1 
cells far outperform β-TC-6 cells in terms of both proliferation and total metabolic rate. Over the 
course of three days, an exponential growth in cell number can be observed, whereas the β-TC-6 cell 
count remains stable. In line with this, the total metabolic rate of MS1 cells increases over time, 
whereas for β-TC-6 cells this even appears to decrease at three days.  
 Decreasing metabolic activity of β-TC-6 cells within three days is a troublesome sign for their 
biological function. However, it needs to be taken into consideration that in order to establish cell 
count, the samples were trypsinised and re-seeded at both one day and three days after the start of 
the experiments. It is possible that the substantial handling of the cells led to some decreased cell 
functionality and hence this may be not be a reliable indication of their metabolic rates if cells were 
left unhandled. MS1 cells may have been less affected by this handling due to their previously 
observed robust proliferative potential (Fig. 8, 9 and 10). Also, it needs to be stressed that the 
suggested decline between β-TC-6 metabolic rate between t =1 and t = 3 days was not statistically 
significant, and is therefore inconclusive. The discrepancy in metabolism and proliferation between 
the two cell types is nonetheless clearly shown and too prominent to be ignored for future co-culture 
experiments. To compensate for this discrepancy, in the following experiments MS1 cells were 








5.4 Bioprinting co-axial fibres with MS1 and β-TC-6 cells 
To evaluate whether the present platform was cell-friendly, encapsulated MS1 and β-TC-6 cells were 
co-printed into fibres in shell and core, respectively. Cell viability was evaluated through live/dead-
staining at t = 1 and t = 7 days (Fig. 12). In order to compensate for the observed discrepancy in 
proliferation and total metabolic rate between MS1 and β-TC-6 cells, cells were encapsulated in a 1: 
6 ratio (MS1 : β-TC-6). 
 Some cell death was expected, considering the shear stress, two crosslinking steps and 
substantial handling of the encapsulated cells during and prior to the printing process. At the day of 
the experiment, there were some additional technical difficulties with the customised DICAB-1 as the 
cooling malfunctioned. This turned out to be a slight design fault, which was resolved later on during 
experiments described below. During this experiment this led to cells being suspended in un-
crosslinked bioink for 2-3 hrs more than intended. This was also expected to substantially affect 
viability. Nonetheless, cells were seen to survive the encapsulation, printing and crosslinking steps 
relatively well at one day post printing (Fig. 12A), although a moderate amount of individual dead 
cells was present as expected. Cells at this stage possessed spherical morphologies and were still 
present in single cell suspension. After seven days (Fig. 12B), cell spreading had occurred to some 
degree. 
 
Since the shell fibre, which contained MS1 cells, fully encloses the core fibre with β-TC-6 cells, the 
different encapsulation concentrations of these two cell types cannot be observed in these images 
recorded through fluorescence microscopy. In order to confirm successful localisation of MS1 and β-
TC-6 cells in shell and core, respectively, additional staining was performed with labelled anti-CD31 
antibodies (an endothelial cell marker) counterstained with DAPI (a general cell nucleus marker) in 
Fig. 11: Cell count (A) and total metabolic rate (B) of MS1 and β-TC-6 cells in traditional 2D-culture over the 
course of three days; 1.6 million cells were initially seeded at t = 0 days. Both cell types were cultured in medium 
optimised for β-TC-6 cells. Total metabolic rate has been calculated as relative to the metabolic rate of the β-TC-
6 cells at t = 1 day (100%). N = 3, error bars denote the 95% confidence interval (CI). Significant differences were 
found through Welch’s robust means test in B.  *, ** and *** denote significant differences at the 0.05, 0.01 and 
0.001 level, respectively. 
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separate samples. However, no green fluorescence corresponding to CD31-positive cells could be 
observed, across various attempts. These results have been exemplified in the supplemental figures 
(Fig. S2).  
CD31 makes up a substantial part of endothelial cell intercellular junctions. Hence, the lack 
of CD31-positive staining may either indicate: i) there are no MS1 cells present; ii)_the MS1 cells have 
not formed any cell junctions due to low cell density; iii) or MS1 cells have lost CD31-expression. As 
it was unlikely that no MS1 cells were present in the fibres, it is reasonable to rule out possibility i). 
Control experiments were performed with MS1 cells in basic 2D cell culture in which CD31 labelling 
was attempted. Here, too, no fluorescence was observed (data not shown). Given the substantial cell-
cell contact in these 2D-culture experiments, it is unlikely that possibility ii) is the sole root-cause of 
failed staining. Thus, it was ultimately hypothesised that MS1 cells had lost CD31-expression, 
considering the relatively high passage number and tumoral origin of MS1 cells,.  
In the future, this experiment may be repeated with a clinically and biologically more 
relevant cell line, such as EPCs used in experiments below. This would allow for more reliable CD31-
expression to allow for visualisation of the localisation of endothelial cells. Optimally, this should be 
recorded through confocal microscopy. As at the time of the experiment such cells were not readily 
available, and due to the limited clinical relevance of MS1 cells, these experiments were ultimately 
discontinued and focus shifted towards experiments with clinically more relevant cells. Due to 
unsuccessful labelling of endothelial cells, it can also not be concluded whether MS1 cells or β-TC-6 
cells, or both, showed cell spreading at t = 7 days (Fig. 12B). This is predominantly attributed to the 
MS1 cells, based on the limited activity of β-TC-6 cells shown previously and previously observed 
behaviour of MS1 cells (Fig. 8 and Fig. 9).  
Notwithstanding the above, sufficient cell viability at one and seven days after printing had 
been confirmed and therefore the present platform was deemed sufficiently cell-friendly in order to 







5.5 3D-printing of murine islets and EPCs 
As a final series of experiments, it was evaluated whether the platform could also support cells that 
are more similar to those used in potential future animal trials and possibly clinical applications. 
Primary EPCs and islets were isolated from mice and encapsulated and printed following similar 
procedures as described above. Constructs of 2 by 2 cm were fabricated consisting of core/shell-
fibres deposited in an x/y-grid (Fig. 13). Due to ethical considerations and material cost of primary 
cells, a limited number of islets and EPCs was available. Therefore, to limit construct size, only single-
layered constructs were fabricated for these experiments. Constructs incorporated 500 islets mL-1 in 
the core fibres and 2.5 million EPCs mL-1 in shell fibres. Furthermore, considering the size of murine 
islets (up to 250 μm diameter), a wider nozzle (inner nozzle diameter: 502 ± 14 µm; outer nozzle 
diameter: 1241 ± 46) µm was employed for these prints compared to previous experiments to limit 
shear stress and risk of clogging. The use of this larger nozzle resulted in slightly larger fibres with a 
diameter of approximately 2 mm.  
Fig. 12: Live/dead staining (calcein AM/PI) of co-printed MS1 and β-TC-6 cells in shell and core respectively, at t = 
0 (A) and t = 7 (B) days. MS1 and β-TC-6 cells were encapsulated and printed in a 1 : 6 ratio and cultured in 







5.5.1 Islet and EPC survival 
Primarily, it was investigated whether primary EPCs and islets would survive the printing and 
crosslinking process. Constructs containing islets, EPCs or both were fabricated and live/dead 
staining was performed at t = 1 and t = 3 days with FDA/PI. Additionally, free-floating islets in culture 
medium were included as a positive control. Originally, all images were intended to be recorded 
through confocal microscopy. However, substantial green background fluorescence was present 
across all images of printed constructs. This suggests that FDA was retained in the scaffolds in spite 
of PBS washes post-staining. As a result, the encapsulated islets and EPCs became impossible to 
image through confocal microscopy with reasonable quality and these were imaged through normal 
fluorescence microscopy. Signal to noise ratio was still relatively low, but noise has been filtered out 
as far as possible without affecting representativity. Examples of unfiltered images can still be found 
in the supplemental figures (Fig. S3). 
At both t = 1 and t = 3 days, free islets appeared as expected104 (Fig. 14D and 15D). Diameters 
of islets were in normal range (50 – 250 μm) and had spherical or slightly elliptical morphologies. 
Islet cells were predominantly alive, with a few individual dead cells reflected as red spots in the 
islets. Some smaller fragments (<50 µm, smaller than islet size) were additionally observed alongside 
islets, which were identified as potentially either residual exocrine pancreatic debris or islet 
fragments. 
 
Fig. 13: A printed construct with encapsulated mouse islets and EPCs in core and shell, respectively (representative 










Due to low signal to noise ratio in the scaffolds, individual live or dead cells could not be visualised 
in printed islets at t = 1 or t = 3 days (Fig. 14A and 14C and Fig. 15A and 15C). However, printed 
islets still appeared predominantly green. Islets thus appear to survive printing and crosslinking 
procedures at one day after printing in at least short-term culture post printing. 
Fig. 14: Live/dead-staining (FDA/PI) of encapsulated and consecutively printed mouse islets (A), EPCs (B), 
islets and EPCs (C) or free-floating islets in culture medium (D) at t = 1 days post-printing. Images recorded 
through fluorescence microscopy (A-C) and confocal microscopy (D). 
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It proved particularly troubling to visualise EPCs as their fluorescence was only marginally 
larger than background. Thus, less noise could be filtered from images incorporating EPCs (Fig. 14B 
and 14C and 15B and 15C). However, small specks can still be observed throughout these constructs 
at both t = 1 and t = 3 days revealing EPCs survived printing and crosslinking. At t = 1 days EPCs were 
present in single cells and no noticeable changes in morphology could be observed within the short 
time frame at t = 3 days. It needs to be mentioned, however, that any conclusions are quite limited 
due to the quality of the images. As no red staining is observed however, the images suggest there 
are few necrotic EPCs. 
 
In fibres with encapsulated EPCs and islets, these data suggest that co-printing and short-term co-
culture had no detrimental effect on viability for either EPCs or islets at t = 1 and t = 3 days (Fig. 14C 
and 15C). These recording suggest that islets and EPCs in co-culture appeared similar to those in 
scaffolds incorporating islets or EPCs alone. Islets were mostly localised at the centre of these fibres, 
Fig. 15: Live/dead-staining (FDA/PI) of encapsulated and consecutively printed mouse islets (A), EPCs (B), 
islets and EPCs (C) or free-floating islets in culture medium (D) at t = 3 days post-printing. Images recorded 




whereas EPCs were present throughout. Thus, some spatial control in localising islets to centres of 
fibres was achieved. Whether EPCs were successfully exclusively localised in shell could not be fully 
concluded due to the nature of fluorescence microscopy and its limited spatial definition along the z-
axis. Thus, as the shell envelops the islets in the core entirely, EPCs observed at the centre of the 
fibres may be above or below the core, but this cannot be fully concluded. 
 
It again needs to be emphasised that the over-all quality of these images is limited, which limits the 
conclusions that can be reliably drawn from these data alone. Therefore, it is recommended that 
similar experiments are conducted in the future in order to confirm these preliminary observations. 
In order to circumvent the present limitations in imaging, the experimental procedures need to be 
optimised to allow for imaging 3D-printed constructs through confocal microscopy, similar to the 
depicted free-floating islets depicted in Fig. 14D and Fig. 15D. The main issue at this stage was 
background noise, which is hypothesised to be caused by retained FDA in the bioink. To this end, in 
particular the staining procedures need to be optimised with improved and prolonged washing steps 
to allow more time for diffusion of FDA out of the printed fibres. If this fails, it may be necessary to 
resort to a different live cell marker such as calcein AM. 
 
5.5.2 Glucose Stimulated Insulin Secretion 
It was next evaluated whether the printed islets also possessed biological functionality. To this end, 
a series of glucose stimulated insulin secretion (GSIS) experiments was performed at t = 1 and t = 3 
days post printing. In two independent experiments consisting of a sample size of three per group, 
constructs were fabricated as described above with encapsulated islets or islets and EPCs. As a 
control, free-floating islets were again included in the study. Islets or constructs were first washed in 
a low glucose buffer and then allowed to recover in low glucose buffer for thirty minutes to allow 
glucose from culture medium to diffuse out of scaffolds. Next, they were again incubated in a buffer 
containing low glucose, for sample collection, before being incubated in a buffer with a high 
concentration of glucose. Insulin secretion in low and high glucose buffers was established with 
sandwich ELISA. 
 These results were expressed in terms of a secretion ratio, defined as the concentration of 
secreted insulin in high glucose divided by the concentration in low glucose. Optimally, in order to 
compensate for varying amounts of islets in constructs or culture, the secretion would be expressed 
per DNA or total protein content.110,113 However, considering the presence of EPCs in one of the 
groups, this could not be used for these experiments. Nonetheless, the secretion ratio still offers some 
insight into the glucose response in insulin secretion.  
There was a striking degree of variance (within groups) in secretion ratios across all groups 
(Fig. 16A). As such, no significant differences were found between groups or time points, and 
apparent trends should not be considered conclusive. There are two potential causes for this high 
variation. First and foremost, it is difficult to control the amounts of islets present in free-floating 
culture and especially in printed constructs. This can lead to substantial variability in the islet counts. 
45 
 
As the secretion ratio does not reliably compensate for islet number, this is prone to increase 
variance within groups. Additionally, some debris of sub-islet size (< 50 µm diameter) was observed 
during islet counts pre-encapsulation, which can also be seen in in the images of free floating islets 
(Fig. 14D and Fig. 15D). This debris may consist of islet fragments or exocrine pancreatic cells. One 
of the functions of exocrine pancreatic cells, is the secretion of digestive enzymes such as proteases. 
These may cleave insulin, rendering it undetectable by ELISA. The protease-activity and amount of 
debris is not accounted for in these assays and it is plausible that this varied per sample and 
experiment. As such, this probably further contributed to the high variance within groups. 
 
Analysis therefore shifted towards the raw data of detected insulin concentrations. As can be 
expected, similar variance was present within groups in these data (Fig. 16B and 16C). As such, the 
data are inconclusive for any trends relating to time point or group. It was however observed that all 
constructs and free-floating islets secrete insulin at levels within the same order of magnitude at both 
timepoints. Surprisingly, insulin secretion in low glucose conditions was comparable to the secretion 
in high glucose conditions in the printed islets (with and without co-printed EPCs). This is contrary 
to the physiological expectations. It is hypothesised that this may be due to the delayed diffusion of 
glucose from culture medium out of the scaffolds during washing before incubation in low glucose 
conditions. It is likely that washing time was insufficient for glucose to diffuse out of the scaffolds, 
resulting in a high-glucose environment from residual glucose despite surrounding buffer with low 
glucose concentrations. This same effect has been reported elsewhere.89 
 In order to circumvent these limitations, washing steps in the protocol might be lengthened 
further in order to allow for diffusion as mentioned above. Another alternative would be to digest the 
scaffolds through the use of enzymes; this has previously been shown to recover glucose response.89 
However, this approach defeats the purpose of the experiment to a major degree, as the main clinical 
interest is in the glucose response of islets while they are encapsulated. This remains a complex 
challenge for the construct design. In future construct designs, the best way to improve encapsulated 
islet GSIS performance, might be to develop functional vasculature. This will be elaborated on in the 
Future Outlook below. 
 
In conclusion, notwithstanding considerable limitations to the conclusions that can be drawn from 
the data, it has been shown that printed islets secrete similar (within an order of magnitude) amounts 
of insulin compared to islets in free-floating culture. Considerable optimisation is still required for 
better output parameters and additional research is required, but the platform has been shown to 






As mentioned in the platform description in Chapter 3, co-printed EPCs may stimulate islet function. 
However, this is not apparent in the data here. In the first place, it is expected that this is due to the 
short culture times. The major advantage of EPCs would be in the development of vascularisation, 
which expectedly did not occur within three days.  
A smaller effect of the presence of endothelial cells is that they affect β-cell behaviour 
through paracrine signalling110,111, but these effects have also not been observed. It may be that the 
three-day time span is similarly insufficient for these effects to take shape, or that the physical 
separation between EPCs and islets in shell and core fibres with delayed diffusion inhibited paracrine 
signalling. Most likely, however, the variance within groups was too substantial to detect any (subtle) 
paracrine signalling effect between islets printed without or with EPCs. It can still be concluded that 
presence of EPCs did not negatively affect islet viabilities as shown in the previous figures, allowing 




Fig. 16: Insulin secretion ratios (A) as well as total 
secreted insulin per group in low glucose solution and 
high glucose solution at t = 1 day (B) and t = 3 days (C), 
detected by sandwich ELISA for mouse insulin. Groups 
consisted of printed islets (Islets only), co-printed 
islets and EPCs (Islets/EPCs) or free-floating islets in 
culture medium (Free Islets). Data displayed as means 
of N = 6 across two independent experiments. Error 
bars denote SD. No significant differences between 




5.5.3 Hypoxia in printed scaffolds 
Hypoxic conditions arising due to limited diffusion are one of the central limitations to tissue 
constructs. For isolated pancreatic islets, oxygen conditions have been shown to be particularly 
central to islet viability.114 Therefore, in a final experiment, the degree of hypoxia was investigated in 
constructs of the same design. However, for easier quantification of data, only EPCs were printed in 
these constructs. Whereas EPCs were confined to the shell fibres in the previous experiment, EPCs 
were printed in both core and shell fibres for these experiments in order to obtain a representation 
of the constructs as a whole. 
 One day after printing, constructs were cultured in normal conditions in medium 
supplemented with a marker for cellular hypoxic conditions. A brighter signal corresponds to 
increased hypoxic conditions. The constructs were imaged with confocal microscopy and compared 
to hypoxic (1% O2) and normoxic (unaltered oxygen levels) controls (Fig. 17) which consisted of 
conventional 2D-cell culture. 
 In the hypoxic control (Fig. 17A), cells can be observed clearly with a bright green 
appearance, as can be expected. Cells appear rounded in single-cell suspension, as cells were 
trypsinised to allow for imaging. There is a small degree of variability in apparent fluorescence, but 
this is mainly related to cells situated in a different z-plane resulting in a dimmer appearance. 
Initially, no signal is apparent in the printed cells (Fig. 17C). This would suggest approximately 
normoxic conditions, considering the similarity with the normoxic control (Fig. 17B). However, as 
fully normoxic conditions throughout the whole construct are unlikely, images were further analysed 
and signals could be visualised in imaging software with considerably increased contrast (Fig. S4). 
The locations where staining of these cells could be detected with increased contrast have been 
highlighted with yellow boxes in the unaltered image. Nonetheless, considering the faint signal, these 
data suggest that conditions are only slightly hypoxic in constructs.  
 
To further elucidate the degree of hypoxia in a more defined manner, quantified data were obtained 
with flow cytometry (Fig. 18). In line with the images displayed in Fig. 17, it was established that 
conditions in constructs were substantially less hypoxic than in hypoxic controls. Interestingly, 
however, in the quantified data constructs were shown to be significantly different from normoxic 
control as well, which confirms that conditions are not fully normoxic in constructs as was previously 
expected. As such, a moderately hypoxic environment is present in the scaffolds. However, based on 
previous experiments (Fig. 8, 14 and 15), it seems that the moderate degree of hypoxia does not 





Fig. 18: Hypoxia in printed scaffolds containing EPCs in core and shell, as compared to EPCs cultured in 2D 
6-well plates in hypoxic conditions (1% O2; hypoxic control) and normal oxygen levels (normoxic control). 
Data have been quantified using flow cytometry, MFI (Mean Fluorescence Intensity) is a measure of hypoxic 
conditions. Error bars denote the 95% CI. Measurements performed in triplicates. *, ** and *** indicate 
significant differences at the 0.05, 0.01 and 0.001 levels, respectively. 
Fig. 17: Hypoxia in printed scaffolds containing 
EPCs in core and shell (C), as compared to EPCs 
cultured in 2D 6-well plates in hypoxic 
conditions (A; 1% O2; hypoxic control) and 
normal oxygen levels (B; normoxic control). 
Cells have been visualised using a marker that 
indicates hypoxic conditions within cells 
(Image-iT green; 1 μL/mL). Yellow boxes in C 
indicate locations where cells have been 
recorded, although fluorescence is hard to 
observe in the unmodified image. The same 
image (C) with boosted contrast can be found 





Here, it has been demonstrated that our platform is capable of bioprinting both single cells derived 
from cell lines and primary islets and EPCs. Although some of the images were of sub-optimal quality, 
it was seen that printed cells and islets possessed good over-all viability.  We have shown that islets 
secrete insulin, but there was substantial variability in the concentrations of secreted insulin and 
glucose response was poor. Various limits are present in the current study, which have been 
summarised below in Table 1. 
 
Various methods have been used in the past to create porous (bio)material scaffolds for 3D-culture 
of islets, such as lyophilisation115. However, in terms of spatial control and definition, these 
fabrication methods are inferior to Biofabrication as wielded here. The first study applying 
Biofabrication for endocrine pancreatic tissue engineering is reported in 2011 by Daoud et al.10 with 
printed PLGA scaffolds. A drawback of the PLGA material choice is that it is not inherently cell-
friendly, which necessitated supplementation of ECM molecules, and its mechanical properties do 
not match soft tissues. After scaffold fabrication, islets were seeded onto these scaffolds. Seeding of 
islets after printing may avoid any loss in function or viability of islets induced through shear stress 
during printing. Due to post-fabrication seeding, however, islets may be localised towards the 
perimeter of the scaffolds, facilitating immune destruction of islets after transplantation. In another 
study, direct printing of the β-cells was also avoided by fabricating a potential transplantation device 
with FDM instead of a tissue construct.90 However, Marchioli et al. reported the first study where 
islets and β-cells were directly bioprinted and it was shown that encapsulation and printing of islets 
was not detrimental to viability.89 This is in line with what we also show here. To our knowledge, this 
remains the only study that has investigated the possibility of directly bioprinting β-cells or islets 
prior to the present thesis. 
The study by Marchioli et al. relied on a similar biomaterial choice for the encapsulation and 
printing of islets as reported here. A hybrid alginate/gelatine bioink was used with slightly different 
concentrations, but the most considerable distinction in material choice is the methacrylation of 
gelatine which we have used here. In previous studies104, it was found that previously used 
gelatine/alginate blends were dissolved and/or disintegrated in vivo. This is likely due to the de-
crosslinking and outwash of alginate in the lower concentration calcium environment in vivo, paired 
with the hydrolysis of gelatine. Introducing a double-crosslinked hydrogel network is hypothesised 
to slow this process down. Although this may require less cell friendly dual crosslinking, we have 
shown here that this does not noticeably affect viability of β- and endothelial cell lines, primary EPCs 








Description of proposed solution(s) and / or future outlook 
Limited temperature 
control of bioink, 
leading to lower 
viscosity with less 
spatial control in ink 
deposition (p. 32) 
Temperature control of the bioink was somewhat challenging in this first design 
iteration of DICAB-1. Printing was feasible with some additional measures (see 5.1.3), 
but this still resulted in limited control over pore size and constraints on construct size 
(number of layers). In next iterations of DICAB, improved design of temperature control 
units will improve control over bioink viscosity, improving over-all print performance. 
No formation of MS1 
or EPC endothelial cell 
network (p. 34 and p. 
43, respectively) 
In encapsulation experiments with MS1 cells, no continuous endothelial cell network 
formation was observed in spite of high proliferation and good cell viability. In future 
experiments, VEGF concentrations may be optimised and visualisation needs to be 
improved with methods such as confocal microscopy to study functional endothelial 
cell network formation. 
In printed constructs, EPCs remained in single cell suspension and showed limited 
bioactivity, with no cell spreading or endothelial network formation. This is due to the 
limited culture times of only several days. In the future, constructs should be cultured 
for several weeks to investigate bioactivity of EPCs.  
These limitations entail that it is currently unproven whether the platform can 
support the formation of endothelial cell networks and this needs to be further 
investigated.  
CD31 staining was not 
detected (p. 38) 
In the future, a clinically and biologically more relevant cell line with lower passage 
number may be used, which is less likely to have lost expression of CD31. Using these 
cells, considerable protocol optimisation should be performed to ensure the staining 
procedure functions optimally. Finally, the lack of expression could be due to the 
downregulation of CD31 given the low density of cells within the construct or the 
absence of junctions, however this seems unlikely as root cause as in 2D-cell culture 
with high cell density no staining was observed either.  
Limited imaging 
quality of printed 
constructs containing 
islets and EPCs (p. 41) 
Whether EPCs were successfully, exclusively localised in the shell of printed fibres 
could not be concluded due to the nature of fluorescence microscopy and its limited 
spatial definition along the z-axis. Moreover, visualisation of EPCs was of limited quality 
due to substantial background fluorescence.  
Therefore, it is recommended experiments are conducted in the future that 
circumvent the present limitations in imaging. Experimental procedures need to be 
optimised to allow for imaging 3D-printed constructs through confocal microscopy. In 
addition, in particular the staining procedures need to be optimised with improved 
and prolonged washing steps to allow more time for diffusion of FDA out of the printed 
fibres or alternative staining procedures need to be considered altogether with e.g. 
calcein AM. 
Limited validation of 
islet/EPC survival (p. 
42) 
In this manuscript, only qualitative evidence of printed islet and EPC survival is 
provided. To further substantiate the biocompatibility of the printing process and the 
bioink with biologically relevant cells, cell viability needs to be quantified for example 
with Fluorescence-Activated Cell Sorting (FACS). Protocols thereto will require 
substantial optimisation with respect to scaffold digestion with proteolytic enzymes to 
break down the GelMA network and ionic de-crosslinking of the alginate network with 
Ca2+-low media, followed by several washing steps. Optimally, culture times of 
scaffolds should be extended to several weeks for these experiments. 
High variance in 
glucose secretion in 
GSIS experiments (p. 
46) 
Due to excessive within-group variance in GSIS experiments, no significant differences 
were found between groups or time points, and apparent trends should not be 
considered conclusive. In order to improve experimental set-up to better assess GSIS, 
various challenges need to be tackled: 
a) The amounts of islets present in free-floating culture and especially in printed 
constructs should be controlled and/or accounted for, in order to express 
secreted insulin per islet in each construct. 
b) Filtration steps prior to encapsulation into bioink need to be performed to 
remove debris of sub-islet size (< 50 µm diameter) which may contain exocrine 
pancreatic tissue (potentially secreting proteolytic enzymes degrading secreted 
insulin) 
c) More extensive washing procedures should be integrated in the experimental 
protocols to allow for glucose diffusion in and out of scaffolds, such that low- 




Encapsulating pancreatic islets for pancreatic tissue engineering remains an active field of study.  
Nonetheless, a major hurdle that needs to be overcome before Biofabricated scaffolds with 
encapsulated islets can move to the clinic, is the glucose-responsivity of the insulin secretion. An 
established minimum for islets to be considered functional is a stimulation index or secretion ratio 
of 2 or more.89,116 We report substantial mean concentrations of secreted insulin (albeit with 
considerable variability) of printed islets; for example three to four fold higher than reported by 
Marchioli et al. in comparable experiments.89 Nonetheless, insulin secretion in high glucose was 
similar to that in low glucose with neither printed islets nor co-printed islets and EPCs reaching mean 
secretion ratios above 1. This is a persistent issue in 3D-printed islets. None of the studies discussed 
so far were able to reach the threshold of secretion ratios or stimulation indices above 2 in printed 
constructs. Although calcium signalling plays a major role in β-cell insulin secretion, it is unlikely to 
be a dominant cause of lower secretion ratios. Low secretion ratios were similarly observed in 
constructs crosslinked with other divalent ions89 and without ionic crosslinking10,89. We and other 
studies therefore hypothesise that lower glucose sensitivity is rather caused by a delayed diffusion 
of glucose into and out of scaffolds, which is further supported by the observation that islet function 
is restored upon re-isolation from scaffolds.89 
 
Although micro-extrusion of encapsulated islets in itself is not new, it is for the first time reported 
here that islets can be co-printed with an additional endothelial cell type. Due to the co-axial nozzle 
set-up, no additional encapsulation steps were required with the same bioink, limiting the handling 
of islets and exposure to radicals and toxic photo-initiator in hydrogels pre-crosslinking. The data 
from MS1 cell encapsulation experiments support that the bioink developed here can support the 
viability and biological activity of endothelial cells during longer culture. It is therefore expected that 
in this platform vascular structures may be formed with EPCs in longer term culture to supply 
nutrients and oxygen to the islets. The development of such vasculature may then in turn overcome 
the limitations to glucose responses associated with delays in diffusion described above.  
In a follow-up study by Marchioli et al. in 2016, the glucose diffusion limit leading to 
decreased islet functionality was also attempted to be overcome through the development of 
vascularisation.117 To this end, VEGF was immobilised on heparin-coated PCL discs surrounding 
islets encapsulated in alginate. Increased development of neovascularisation was observed and islets 
were substantially more functional with higher stimulation indices. These findings support the 
notion that improved vascularisation over longer-term culture in the constructs may enhance islet 
function in vivo in the future in this platform as well. Our platform offers an added benefit in that 
these constructs may be fabricated in a single step through co-axial extrusion, whereas those 
proposed by Marchioli et al. require several additional steps with increased fabrication times.  
 
Although vascularisation is likely to increase glucose-dependent insulin responses, an additional 
complication that arises is that it also exposes islets to the host immune system after anastomosis. In 
light of this, a few macro-encapsulation strategies have attempted to combine development of 
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vascularisation with immune-shielding by incorporating two membranes118,119. The outer membrane 
would have pores that are large enough to allow for vascularisation, whereas the inner membrane 
pore size would be small enough to block even humoral immune agents. Nonetheless, this 
considerably complicates the fabrication process and the second membrane for shielding is still likely 
to slow down diffusion. For our platform, we therefore envision an alternative strategy in the future 
that may resolve the threat of immune-destruction enabled by vascularisation, which will be 
elaborated on in the future outlook below. 
 
It becomes apparent that the central benefit of the proposed platform here is the relatively simple 
fabrication, while still allowing for the co-delivery of islets and endothelial cells through co-axial 
extrusion. Co-axial micro-extrusion has been used previously for various applications, including for 
endocrine pancreatic engineering in 2015, where hollow alginate tubes were fabricated by extruding 
sodium alginate through a shell nozzle with crosslinking solution in the core.88 The tubes were 
consecutively used for the culturing of tissue strands incorporating β-TC3 cells or fibroblasts. Here, 
it has been demonstrated that co-axial extrusion cannot be used only for the fabrication of a culture 
mould, but even for direct co-printing of β-cells or islets with endothelial cells, in a single-step 
fabrication. 
 
In one of the additional experiments performed here, the degree of hypoxia throughout the 
constructs was evaluated. It is well established that hypoxia has a major detrimental effect on islet 
viability and function. Based on viabilities post printing and during culture, it was already expected 
that hypoxia would be minor. This was confirmed qualitatively and quantitatively. Nonetheless, it 
needs to be mentioned that these constructs only consisted of a single layer, and it can be expected 
that hypoxia may increase moderately as construct sizes increase with additional layers. Conversely, 
the development of vascularisation, which the proposed bioink supports as the data suggest here, 








7. Future Outlook 
Several central hurdles still exist for the field of Biofabrication at large, such as the reliable 
development of vascular trees and innervation as well as standardisation of procedures and 
scalability. These future directions have been elaborately described elsewhere and will not be 
repeated further here.31,82 However, based on the data presented here, various recommendations can 
be made towards the future progress of this project in particular. Here, some short recommendations 
for follow-up experiments will be touched upon as well as some recommendations towards future 
standardisation and optimisation of several parameters in the platform. Finally, it will be envisioned 
how an ultimate construct design from this platform could take shape that meets all requirements 
identified at the start of this thesis (Fig. 1). 
 
7.1 Follow-up experiments 
In this thesis, it has been described that endothelial cells show substantial cell spreading and 
alignment after three weeks of culture. This demonstrates that cells survive in the material for longer 
culture durations and suggests that the hydrogel may support the development of functional 
vascularisation in the future. However, to conclusively demonstrate the latter, additional 
experiments are required with also clinically more relevant cell types. It is recommended that 
commercially available angiogenesis assays are performed with for example HUVECs (human 
umbilical cord endothelial cells) or EPCs. It should then also be confirmed that the printing process 
does not affect angiogenesis and it may be interesting to compare printed and mould-casted 
constructs in light of this. In order to fully confirm functionality of observed structures, it is 
additionally recommended that lumen formation is visualised with confocal microscopy. 
 Some initial insight has been offered here into the establishment of an MS1/β-TC-6 co-
culture as a model system. Although a quantifiable indication has been established of the relative 
metabolism and proliferation of these cell types and a suitable co-culture medium has been found, 
this co-culture system could be further optimised by attempting various cell encapsulation/printing 
ratios and tracking cell survival of both cell types over time. It may be argued that a cell line based 
co-culture platform has become obsolete since compatibility of the platform with more relevant cells 
including primary islets and EPCs has been confirmed. Taking some ethical considerations in mind, 
however, further development of the co-culture platform with cell lines may be useful for future, 
more preliminary, optimisation and platform developing experiments to limit animal use and it will 
be considerably more cost-effective for these experiments. It needs to be pointed out that for further 
optimisation of the co-culture platform, a more sophisticated experimental set-up may be necessary 
than used here. The experiment here was only designed to offer an indication, whereas more accurate 
cell counts and viability counts may be obtained for example with flow cytometry in the future. 
Tying in with these co-culture considerations, it was attempted here to track MS1 and β-TC-
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6 cell fate to some degree through fluorescent labelling of CD31 on MS1 cells. This was ultimately 
unsuccessful. Establishing a functional protocol for distinguishing these cells will be required for 
tracking their fates independently. Additionally, this could confirm the successful localisation of the 
different cell types to core and shell fibres, which to date has only been confirmed reliably for labelled 
bioink without encapsulated cells. 
 
One of the key findings here is that primary islets survive encapsulation, printing and crosslinking, 
which is the first and essential step in the development of this platform for endocrine pancreatic 
tissue engineering. Nonetheless, it generates more questions than it answers. Essential follow-up 
questions will be whether islets survive longer term culture in the constructs of several weeks or 
whether the moderate hypoxia and hypothesised delayed nutrient diffusion will lead to necrotic core 
formation at the construct or islet level after such time.  
Additionally, major variance in insulin secretion and glucose response are reported here. It 
needs to be established whether these can be diminished. One suggestion to this end is to filter 
isolated islets with a 40-μm filter and discard the filtrate, which will contain apoptotic islet fragments 
and protease-secreting remnants of the exocrine pancreata. As previously mentioned, the 
inconsistent presence of especially exocrine cells between samples is hypothesised to have made a 
major contribution to the observed variance.  Additionally, methods can be devised to express 
secretion in stimulation indices by compensating for islet count. This may be a complicated 
endeavour nonetheless, considering the presence of additional cell types in some groups. This 
renders a total protein or DNA count an inadequate measure for islet count. At the present time, no 
method was yet available for such compensation. A manual count of islets per construct may be an 
option with light or confocal microscopy, but this may be time-consuming, labour-intensive, 
subjective and moderately unreliable. 
 
 As a final recommendation for a follow-up experiment, some more investigation into the hypoxia in 
scaffolds may be interesting. Here, EPCs were printed in both core and shell fibres and then 
collectively assessed for hypoxic conditions, offering a picture of hypoxia in the scaffold as a whole. 
The same experiments can be conducted with EPCs printed exclusively in core or shell, which will 
demonstrate if there is a significant difference in hypoxia between the core and shell fibres, which 
will offer some additional insight into the efficiency of oxygen diffusion into the constructs. 
Furthermore, as different cell types are differently affected by hypoxic conditions, it may be 
interesting to repeat these experiments with β-cells or islets. 
 
7.2 Standardisation and optimisation 
For this thesis, a broad range of different experiments has been performed in a moderately limited 
amount of time. Although this resulted in several useful proof-of-concepts, the time restriction led to 
some experiments being performed with parameters established through trial and error, rather than 
systematic optimisation. Considering the collaboration between the different institutions, 
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standardisation and optimisation is required for the progress of the project. 
 Primarily, the preparation and handling of the bioink needs to be optimised and 
standardised. It was observed that there was substantial variability in preparation methods between 
researchers from the different institutes, in addition to the use of different suppliers for some of the 
reagents. Although some batch to batch variability is unavoidable, in part due to variability in 
different batches of prepared GelMA for example, bioink behaviour was observed to vary 
substantially between batches. For example, it was reported here that substantial a-specific staining 
of bioink was consistently observed with FDA, whereas previous studies reported no such 
observations in spite of similar staining procedures.104 Additional parameters for bioink handling 
that need to be optimised and standardised are crosslinking time (ionic and photo-crosslinking), light 
intensity and distance (photo-crosslinking) and photo-initiator concentrations. These parameters 
need to be optimised for cellular response and mechanical properties. Additionally, it can be 
optimised for scaffold porosity and interconnectivity after crosslinking. Although some insight has 
been offered previously through SEM104,  SEM has a major impact on the microstructure of hydrated 
samples and does not accurately represent porosity in hydrated conditions. A useful alternative may 
be to investigate the hydrogel microstructure through scanning electron cryomicroscopy (SECM), 
which avoids distortion from dehydration. SECM would be a suitable method to investigate pore sizes 
across different crosslinking parameters, which can then be optimised.  
 
Finally, additional standardisation can be performed for printing procedures. Particularly, bioink 
temperatures during printing were only defined by system settings, which were expected to vary 
substantially from actual cartridge temperatures. This was further exacerbated by intermittent 
placing on ice during the islet printing experiments for additional cooling. Although DICAB-1 at the 
time of writing of this thesis has become obsolete with the arrival of the next generation (DICAB-2) 
with improved temperature regulation, it is necessary that the cartridge temperatures for this new 
system are accurately identified as related to the system temperature settings for reproducibility. 
Additionally, some of the standardisations and characterisations performed here for DICAB-1 will 
need to be repeated for DICAB-2. 
 
7.3 Future construct design 
At the start of this thesis, the requirements for a successful tissue engineered and/or Biofabricated 
construct of the endocrine pancreas were identified (Fig. 1). The construct design as presented in 
the final experiments described here, can be seen to only partially fulfil these requirements. First, it 
meets a requirement in that it allows for sufficient diffusion of oxygen and nutrients for cell and islet 
survival based on the hypoxia experiments and viabilities in fibres and constructs. Second, it has been 
shown that endothelial cells survive sufficiently long and in future experiments more steps can be 
made towards development of vascularisation (the second identified requirement). The two 
requirements for a successful endocrine pancreatic tissue construct that are wholly lacking in the 
present construct design are glucose sensitivity and immune-protection. 
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A future construct design has been envisioned which may live up to all the requirements (Fig. 19). 
This design will be the convergence of this project in the present thesis and several projects running 
in parallel at the University of Adelaide. To provide immune-protection, T-regs may be incorporated 
into the tissue construct to stimulate tolerogenesis. T-reg behaviour in the GelMA/alginate bioink is 
currently being investigated at the University of Adelaide. Further, it will be beneficial to incorporate 
EPCs in both core and shell fibres to allow for development of vascularisation throughout the 
construct. Although EPCs were contained in the shell here as a proof of concept, fully-developed 
vascularisation through core and shell could enable increased diffusion rates, which in turn may 
increase GSIS and will positively affect islet survival. Islets would still be incorporated in the core, 
whereas T-regs may be localised in the shell of the fibres. The constructs could then still be fabricated 
in a single printing step by depositing the fibres in x/y-grids and stacking into several layers. If T-reg 
tolerogenesis and formation of vascularisation can then be optimised, a construct design may be 
feasible which meets all requirements. 
 
As a final remark, it needs to be noted that the application of this design would still be limited as the 
general shortage in allogeneic islets would still prevent wide-scale application. This may be 
circumvented by using pseudo-islets or islet-like organoids derived from ESCs or iPSCs in an ultimate 
construct design. Major steps have been made in developing these tissues and optimising their 
GSIS.42–45,120 As an additional advantage of this construct design, the risks associated with their use 
(for example teratoma formation) may be more limited due to the encapsulation and thereby 








Fig. 19: A schematic representation of a potential future construct design, which may meet 
all requirements for a successful Biofabricated endocrine pancreatic tissue construct. A 
top-view is provided in B. Tregs and EPCs would be located in the shell of the fibres (blue), 
(pseudo-)islets and EPCs would be located in the core of the fibres (green). Shells would be 





A platform for the fabrication of endocrine pancreatic tissue constructs through co-axial micro-
extrusion was developed. It was shown that the custom printing set-up, DICAB-1, can print co-axial 
fibres with Pluronic as well as GelMA/alginate bioink, and is capable of printing both β-cell lines and 
endothelial cell lines with good viability. It was further demonstrated in encapsulation experiments 
that the GelMA/alginate bioink can sustain long-term culture and steps have been made towards 
developing a co-culture platform of MS1 endothelial and β-TC-6 cells. 
In addition, primary murine islets and isolated endothelial progenitor cells have been printed 
into core/shell-constructs with good viability. Islets were shown to secrete substantial amounts of 
insulin. The degree of hypoxia in printed scaffolds has been evaluated qualitatively and 
quantitatively; it was found that conditions were mildly hypoxic but this did not appear to have 
affected short-term islet viability in earlier experiments. However, glucose response of printed islets 
was poor. A potential construct design in the future is however envisioned which may improve 
insulin secretion dynamics and provide immune-protection through tolerogenesis, thus meeting all 
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Appendix 1: Supplementary Figures 
 




Fig. S1: Fibre diameters of extruded Pluronic F-127 fibres with a 1:1 
core/shell ratio at various extrusion rates. Feed rate 400 mm/min with a 
build plate distance of 0.9 mm. Error bars represent 95% CI, N = 6. In later 
prints, relying on more suitable core/shell-extrusion ratios, consistency in 




Supplementary Figure 2: 
  
Fig. S2: Co-axially printed fibre with encapsulated MS1 endothelial and β-TC-6 cells. Stained with 
DAPI (blue) and FITC-labelled anti-CD31 antibodies (green). There is substantial blue staining, 
indicating presence of cells. However, there is no green staining, with the exception of some very 
subtle background noise, indicating no CD31-positive cells. This may either indicate there are no 
MS1 cells present or MS1 cells have lost CD31-expression. Both are unlikely, it is therefore thought 
that staining procedure has failed due to some unknown reason. Time was too limited for extensive 
trouble-shooting and this question remains to be answered. 
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Supplementary Figure 3: 
  
Fig. S3: Original microscopy images without noise filtering, exemplified by islets 
only at t = 1 days (A) and EPCs only at t = 1 days (B), corresponding to Fig. 14A 
and 14B in the main text, respectively. The same noise filters have been applied 
to all images in Fig. 14  and Fig. 15 in the main text, in order to visualise some 
images more clearly without altering the general representation in the images. 
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Fig. S4A-C: Examples of pictures of EPCs cultured in scaffolds with hypoxia 
with boosted contrast in imaging software. When close attention is paid to 
the images, faint green spots can be detected in all three images. B is derived 
from Fig. 17C. 
Fig. S4D: An example of negative control (normoxia) with the same boosted 
contrast. No green spots can be observed. Derived from Fig. 17B. 
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Appendix 2: G-codes for prints 
All G-codes for prints in this thesis were coded manually without CAD or slicing software. The codes 
have been provided below. 
 



























G-codes for the consecutive layers in x and y can be obtained by changing the z-offset from 0.7 to 1.2 
and 1.5 for both x and y for a total construct of six layers. All G-codes above were optimised for the 




Islet print G-codes 










Appendix 3: Biofabrication Double Degree First Thesis – Utrecht 
University 
 
The document in the Appendix below is the manuscript that was completed at Utrecht University as 
a part of the Biofabrication Double Degree (see Biofabrication Double Degree statement at the 
beginning of this thesis). It is included for reference, but should not be taken into further account for 
the review of this thesis as it has already been reviewed in a separate procedure at Utrecht University. 
